α-PHP
α-pyrrolidinohexiophenone
Studies and references cited across this article, graded by evidence strength.
Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.
Data points an editor reviewed and accepted for publication.
Value Provenance
Dosing
insufflatedtrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Threshold | 2 mg | 2 mg | low |
| Low | 4–10 mg | 4–10 mg | low |
| Common | 10–20 mg | 10–20 mg | low |
| Strong | 20–35 mg | 20–35 mg | low |
| Heavy | 35+ mg | 35+ mg | low |
| Editorial | Community-sourced dose ranges from Dinis et al. 2024 review (nasal/sublingual/rectal grouped). Not validated in controlled human pharmacology studies. | ||
ReasoningReasoningCommunity-sourced dose ranges from Dinis et al. 2024 review (nasal/sublingual/rectal grouped). Not validated in controlled human pharmacology studies. Evidence basis: community_consensus_small | |||
sublingualtrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Threshold | 2 mg | 2 mg | low |
| Low | 4–10 mg | 4–10 mg | low |
| Common | 10–20 mg | 10–20 mg | low |
| Strong | 20–35 mg | 20–35 mg | low |
| Heavy | 35+ mg | 35+ mg | low |
| Editorial | Community-sourced dose ranges from Dinis et al. 2024 review (grouped with nasal/rectal). Not validated in controlled human pharmacology studies. | ||
ReasoningReasoningCommunity-sourced dose ranges from Dinis et al. 2024 review (grouped with nasal/rectal). Not validated in controlled human pharmacology studies. Evidence basis: community_consensus_small | |||
rectaltrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Threshold | 2 mg | 2 mg | low |
| Low | 4–10 mg | 4–10 mg | low |
| Common | 10–20 mg | 10–20 mg | low |
| Strong | 20–35 mg | 20–35 mg | low |
| Heavy | 35+ mg | 35+ mg | low |
| Editorial | Community-sourced dose ranges from Dinis et al. 2024 review (grouped with nasal/sublingual). Not validated in controlled human pharmacology studies. | ||
ReasoningReasoningCommunity-sourced dose ranges from Dinis et al. 2024 review (grouped with nasal/sublingual). Not validated in controlled human pharmacology studies. Evidence basis: community_consensus_small | |||
intravenoustrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Threshold | 1 mg | 1 mg | low |
| Low | 3–6 mg | 3–6 mg | low |
| Common | 6–15 mg | 6–15 mg | low |
| Strong | 15–25 mg | 15–25 mg | low |
| Heavy | 25+ mg | 25+ mg | low |
| Editorial | Community-sourced dose ranges from Dinis et al. 2024 review (IV/inhaled grouped). Not validated in controlled human pharmacology studies. Safety-critical: IV route carries highest acute risk. | ||
ReasoningReasoningCommunity-sourced dose ranges from Dinis et al. 2024 review (IV/inhaled grouped). Not validated in controlled human pharmacology studies. Safety-critical: IV route carries highest acute risk. Evidence basis: community_consensus_small | |||
oraltrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Threshold | 3 mg | 3 mg | low |
| Low | 5–15 mg | 5–15 mg | low |
| Common | 10–25 mg | 10–25 mg | low |
| Strong | 25–40 mg | 25–40 mg | low |
| Heavy | 40+ mg | 40+ mg | low |
| Editorial | Community-sourced dose ranges from Dinis et al. 2024 review. Not validated in controlled human pharmacology studies. Threshold 3-5 mg, light 5-15 mg, common 10-25 mg, strong 25-40 mg, heavy >40 mg. | ||
ReasoningReasoningCommunity-sourced dose ranges from Dinis et al. 2024 review. Not validated in controlled human pharmacology studies. Threshold 3-5 mg, light 5-15 mg, common 10-25 mg, strong 25-40 mg, heavy >40 mg. Evidence basis: community_consensus_small | |||
smokedtrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Threshold | 1 mg | 1 mg | low |
| Low | 3–6 mg | 3–6 mg | low |
| Common | 6–15 mg | 6–15 mg | low |
| Strong | 15–25 mg | 15–25 mg | low |
| Heavy | 25+ mg | 25+ mg | low |
| Editorial | Community-sourced dose ranges from Dinis et al. 2024 review (grouped with IV as inhaled). Not validated in controlled human pharmacology studies. Abbreviated duration confirmed by Taffe 2021 animal data. | ||
ReasoningReasoningCommunity-sourced dose ranges from Dinis et al. 2024 review (grouped with IV as inhaled). Not validated in controlled human pharmacology studies. Abbreviated duration confirmed by Taffe 2021 animal data. Evidence basis: community_consensus_small | |||
Duration
intravenous
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| After effectstrace | 2–5 hours | 2–5 hours | low |
| Editorial | Community-sourced afterglow from Dinis et al. 2024 review (IV/inhaled grouped). | ||
ReasoningReasoningCommunity-sourced afterglow from Dinis et al. 2024 review (IV/inhaled grouped). Evidence basis: community_consensus_small | |||
| Onsettrace | 0.5–2 minutes | 0.5–2 minutes | low |
| Editorial | Community-sourced from Dinis et al. 2024 review (IV/inhaled grouped). Near-immediate onset expected for IV. | ||
ReasoningReasoningCommunity-sourced from Dinis et al. 2024 review (IV/inhaled grouped). Near-immediate onset expected for IV. Evidence basis: community_consensus_small | |||
| Peaktrace | 30–90 minutes | 30–90 minutes | low |
| Editorial | Community-sourced from Dinis et al. 2024 review (IV/inhaled grouped). | ||
ReasoningReasoningCommunity-sourced from Dinis et al. 2024 review (IV/inhaled grouped). Evidence basis: community_consensus_small | |||
| Totaltrace | 2–7 hours | 2–7 hours | low |
| Editorial | Estimated from onset + peak + afterglow. Work-notes estimate 2-7 h. | ||
ReasoningReasoningEstimated from onset + peak + afterglow. Work-notes estimate 2-7 h. Evidence basis: community_consensus_small | |||
oral
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Onsettrace | 15–45 minutes | 15–45 minutes | low |
| Editorial | Community-sourced from Dinis et al. 2024 review. Not validated in controlled human pharmacology study. | ||
ReasoningReasoningCommunity-sourced from Dinis et al. 2024 review. Not validated in controlled human pharmacology study. Evidence basis: community_consensus_small | |||
| Peaktrace | 4–6 hours | 4–6 hours | low |
| Editorial | Community-sourced from Dinis et al. 2024 review. Not validated in controlled human pharmacology study. | ||
ReasoningReasoningCommunity-sourced from Dinis et al. 2024 review. Not validated in controlled human pharmacology study. Evidence basis: community_consensus_small | |||
| Totaltrace | 8–16 hours | 8–16 hours | low |
| Editorial | Estimated from onset + peak + afterglow durations in Dinis 2024. Not directly reported. Work-notes estimate 8-16 h. | ||
ReasoningReasoningEstimated from onset + peak + afterglow durations in Dinis 2024. Not directly reported. Work-notes estimate 8-16 h. Evidence basis: community_consensus_small | |||
| After effectstrace | 4–10 hours | 4–10 hours | low |
| Editorial | Community-sourced afterglow duration from Dinis et al. 2024 review. | ||
ReasoningReasoningCommunity-sourced afterglow duration from Dinis et al. 2024 review. Evidence basis: community_consensus_small | |||
insufflated
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Onsettrace | 5–15 minutes | 5–15 minutes | low |
| Editorial | Community-sourced from Dinis et al. 2024 review (nasal/sublingual route). | ||
ReasoningReasoningCommunity-sourced from Dinis et al. 2024 review (nasal/sublingual route). Evidence basis: community_consensus_small | |||
| Peaktrace | 2–4 hours | 2–4 hours | low |
| Editorial | Community-sourced from Dinis et al. 2024 review (nasal/sublingual route). | ||
ReasoningReasoningCommunity-sourced from Dinis et al. 2024 review (nasal/sublingual route). Evidence basis: community_consensus_small | |||
| Totaltrace | 6–14 hours | 6–14 hours | low |
| Editorial | Estimated from onset + peak + afterglow durations. Work-notes estimate 6-14 h. | ||
ReasoningReasoningEstimated from onset + peak + afterglow durations. Work-notes estimate 6-14 h. Evidence basis: community_consensus_small | |||
| After effectstrace | 4–10 hours | 4–10 hours | low |
| Editorial | Community-sourced afterglow duration from Dinis et al. 2024 review. | ||
ReasoningReasoningCommunity-sourced afterglow duration from Dinis et al. 2024 review. Evidence basis: community_consensus_small | |||
smoked
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Onsettrace | 0.5–2 minutes | 0.5–2 minutes | low |
| Editorial | Community-sourced from Dinis et al. 2024 review (inhaled route). Abbreviated onset confirmed by Taffe 2021 animal data. | ||
ReasoningReasoningCommunity-sourced from Dinis et al. 2024 review (inhaled route). Abbreviated onset confirmed by Taffe 2021 animal data. Evidence basis: community_consensus_small | |||
| Peaktrace | 30–90 minutes | 30–90 minutes | low |
| Editorial | Community-sourced from Dinis et al. 2024 review (IV/inhaled route). Abbreviated duration consistent with Taffe 2021 animal data. | ||
ReasoningReasoningCommunity-sourced from Dinis et al. 2024 review (IV/inhaled route). Abbreviated duration consistent with Taffe 2021 animal data. Evidence basis: community_consensus_small | |||
| Totaltrace | 2–7 hours | 2–7 hours | low |
| Editorial | Estimated from onset + peak + afterglow. Work-notes estimate 2-7 h. | ||
ReasoningReasoningEstimated from onset + peak + afterglow. Work-notes estimate 2-7 h. Evidence basis: community_consensus_small | |||
| After effectstrace | 2–5 hours | 2–5 hours | low |
| Editorial | Community-sourced afterglow from Dinis et al. 2024 review (inhaled route). | ||
ReasoningReasoningCommunity-sourced afterglow from Dinis et al. 2024 review (inhaled route). Evidence basis: community_consensus_small | |||
Safety
Toxicity Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Acute | high | high | medium |
| Chronic | moderate | moderate | medium |
| Organs Affected | cardiovascular, central nervous system, musculoskeletal, reproductive | cardiovascular, central nervous system, musculoskeletal, reproductive | medium |
| Editorial | Acute toxicity rated high based on documented cardiovascular toxidrome, hyperthermia, and rhabdomyolysis in Grapp 2023 (n=29) and Bassi 2025 poison centre data, plus fetal death case (Adamowicz 2019). Chronic rated moderate based on in vitro genotoxicity of metabolites (Lenzi 2021) and inferred neurotoxicity from sustained DAT blockade. Confidence medium due to near-universal polydrug confounding in case series and absence of controlled toxicity studies. | ||
ReasoningReasoningAcute toxicity rated high based on documented cardiovascular toxidrome, hyperthermia, and rhabdomyolysis in Grapp 2023 (n=29) and Bassi 2025 poison centre data, plus fetal death case (Adamowicz 2019). Chronic rated moderate based on in vitro genotoxicity of metabolites (Lenzi 2021) and inferred neurotoxicity from sustained DAT blockade. Confidence medium due to near-universal polydrug confounding in case series and absence of controlled toxicity studies. Evidence basis: published_case_series | |||
Dependence Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Physical | low | low | low |
| Psychological | high | high | low |
| Compulsive Redosing | high | high | low |
| Dose Escalation | moderate | moderate | low |
| Editorial | No substance-specific human dependence data published. Physical dependence rated low by analogy with cocaine/methamphetamine. Psychological dependence rated high based on ICSS data (Taffe 2021) showing abuse liability equivalent to α-PVP and methamphetamine, combined with slow-koff DAT kinetics (Niello 2023). Compulsive redosing rated high from clinical pattern and pharmacological mechanism. All values inferred from α-PVP, cocaine, and methamphetamine analogy. | ||
ReasoningReasoningNo substance-specific human dependence data published. Physical dependence rated low by analogy with cocaine/methamphetamine. Psychological dependence rated high based on ICSS data (Taffe 2021) showing abuse liability equivalent to α-PVP and methamphetamine, combined with slow-koff DAT kinetics (Niello 2023). Compulsive redosing rated high from clinical pattern and pharmacological mechanism. All values inferred from α-PVP, cocaine, and methamphetamine analogy. Evidence basis: structural_analogy | |||
Withdrawal Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Severity | moderate | moderate | low |
| Symptoms | dysphoria, anhedonia, fatigue, hypersomnia, depression, irritability, psychomotor retardation | dysphoria, anhedonia, fatigue, hypersomnia, depression, irritability, psychomotor retardation | low |
| Fatal | No | No | low |
| Medical Supervision | Not required | Not required | low |
| Editorial | No substance-specific withdrawal data published. All values inferred from cocaine and methamphetamine withdrawal characterization. Onset estimated at hours after last dose (cocaine analogy); peak at 2-4 days; total duration days to weeks. Severity moderate by analogy — dopaminergic stimulant withdrawal is primarily psychological, not life-threatening. | ||
ReasoningReasoningNo substance-specific withdrawal data published. All values inferred from cocaine and methamphetamine withdrawal characterization. Onset estimated at hours after last dose (cocaine analogy); peak at 2-4 days; total duration days to weeks. Severity moderate by analogy — dopaminergic stimulant withdrawal is primarily psychological, not life-threatening. Evidence basis: structural_analogy | |||
Tolerance Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Buildup | moderate | moderate | low |
| Half-life | — | — | low |
| Full Reset | 14 days | 14 days | low |
| Cross-tolerances | cocaine, methylphenidate, α-PVP, pyrovalerone, MDPV, other pyrovalerone cathinones | cocaine, methylphenidate, α-PVP, pyrovalerone, MDPV, other pyrovalerone cathinones | low |
| Editorial | No published tolerance data for α-PHP. Moderate buildup inferred from DAT-blocker class (cocaine, methamphetamine). Full reset of ~1-2 weeks inferred from cocaine analogy. Cross-tolerances predicted from shared DAT/NET mechanism with listed compounds. | ||
ReasoningReasoningNo published tolerance data for α-PHP. Moderate buildup inferred from DAT-blocker class (cocaine, methamphetamine). Full reset of ~1-2 weeks inferred from cocaine analogy. Cross-tolerances predicted from shared DAT/NET mechanism with listed compounds. Evidence basis: structural_analogy | |||
Effects & Profile
Contraindications
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| neurological Seizure disorderstrace | relative | relative | low |
| Editorial | Class inference from cathinone seizure threshold reduction (Daziani et al. 2023 systematic review). No substance-specific seizure data for α-PHP. | ||
ReasoningReasoningClass inference from cathinone seizure threshold reduction (Daziani et al. 2023 systematic review). No substance-specific seizure data for α-PHP. | |||
| other Concurrent MAOI usetrace | absolute | absolute | medium |
| Editorial | Class inference from DAT/NET-blocking stimulant + MAOI interaction. Documented for cocaine and cathinone class (Daziani et al. 2023). Not substance-specific but mechanism is well-established. | ||
ReasoningReasoningClass inference from DAT/NET-blocking stimulant + MAOI interaction. Documented for cocaine and cathinone class (Daziani et al. 2023). Not substance-specific but mechanism is well-established. | |||
| pregnancy breastfeeding Pregnancytrace | absolute | absolute | medium |
| Editorial | Single case report of fetal death (polydrug context) plus meconium-confirmed neonatal exposure in two cases. Sympathomimetic mechanism independently poses fetal hemodynamic risk. | ||
ReasoningReasoningSingle case report of fetal death (polydrug context) plus meconium-confirmed neonatal exposure in two cases. Sympathomimetic mechanism independently poses fetal hemodynamic risk. | |||
| pregnancy breastfeeding Breastfeedingtrace | absolute | absolute | low |
| Editorial | Class inference from lipophilic stimulant properties plus meconium data confirming fetal exposure. No direct breast milk data but precautionary absolute contraindication warranted. | ||
ReasoningReasoningClass inference from lipophilic stimulant properties plus meconium data confirming fetal exposure. No direct breast milk data but precautionary absolute contraindication warranted. | |||
| cardiovascular Severe cardiovascular diseasetrace | absolute | absolute | medium |
| Editorial | Documented cardiovascular toxidrome in multiple clinical case series. Mechanism (DAT/NET blockade) directly produces sympathomimetic cardiovascular activation. | ||
ReasoningReasoningDocumented cardiovascular toxidrome in multiple clinical case series. Mechanism (DAT/NET blockade) directly produces sympathomimetic cardiovascular activation. | |||
| psychiatric Psychotic disorderstrace | relative | relative | medium |
| Editorial | Hallucinations, paranoia, and delirium documented across multiple clinical case series. Mechanism (excessive dopaminergic stimulation) is consistent with psychotomimetic risk. | ||
ReasoningReasoningHallucinations, paranoia, and delirium documented across multiple clinical case series. Mechanism (excessive dopaminergic stimulation) is consistent with psychotomimetic risk. | |||
| psychiatric Bipolar disordertrace | relative | relative | low |
| Editorial | Class inference from stimulant-induced mania risk. No substance-specific data for α-PHP and bipolar disorder. | ||
ReasoningReasoningClass inference from stimulant-induced mania risk. No substance-specific data for α-PHP and bipolar disorder. | |||
| hepatic Hepatic impairmenttrace | relative | relative | low |
| Editorial | Class inference based on extensive hepatic metabolism documented for α-PHP. Genotoxic metabolites identified in vitro add concern for altered metabolite profiles in hepatic impairment. | ||
ReasoningReasoningClass inference based on extensive hepatic metabolism documented for α-PHP. Genotoxic metabolites identified in vitro add concern for altered metabolite profiles in hepatic impairment. | |||
| renal Renal impairmenttrace | relative | relative | low |
| Editorial | Class inference from absence of renal excretion data combined with extensive metabolite production. Precautionary relative contraindication. | ||
ReasoningReasoningClass inference from absence of renal excretion data combined with extensive metabolite production. Precautionary relative contraindication. | |||
Timeline Phases
insufflated
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Come uptrace | 300–900 sec(i=0.60) | 300–900 sec(i=0.60) | low |
| Editorial | Insufflated timeline from Dinis et al. 2024 review (nasal/sublingual community data). Onset 5-15 min, peak 2-4 h, afterglow 4-10 h. Come-up and offset estimated. No controlled human data. | ||
ReasoningReasoningInsufflated timeline from Dinis et al. 2024 review (nasal/sublingual community data). Onset 5-15 min, peak 2-4 h, afterglow 4-10 h. Come-up and offset estimated. No controlled human data. Evidence basis: community_consensus_small | |||
| Peaktrace | 7200–14400 sec(i=1.00) | 7200–14400 sec(i=1.00) | low |
| Editorial | Insufflated timeline from Dinis et al. 2024 review (nasal/sublingual community data). Onset 5-15 min, peak 2-4 h, afterglow 4-10 h. Come-up and offset estimated. No controlled human data. | ||
ReasoningReasoningInsufflated timeline from Dinis et al. 2024 review (nasal/sublingual community data). Onset 5-15 min, peak 2-4 h, afterglow 4-10 h. Come-up and offset estimated. No controlled human data. Evidence basis: community_consensus_small | |||
| Resolutiontrace | 3600–7200 sec(i=0.40) | 3600–7200 sec(i=0.40) | low |
| Editorial | Insufflated timeline from Dinis et al. 2024 review (nasal/sublingual community data). Onset 5-15 min, peak 2-4 h, afterglow 4-10 h. Come-up and offset estimated. No controlled human data. | ||
ReasoningReasoningInsufflated timeline from Dinis et al. 2024 review (nasal/sublingual community data). Onset 5-15 min, peak 2-4 h, afterglow 4-10 h. Come-up and offset estimated. No controlled human data. Evidence basis: community_consensus_small | |||
| Onsettrace | 300–900 sec(i=0.30) | 300–900 sec(i=0.30) | low |
| Editorial | Insufflated timeline from Dinis et al. 2024 review (nasal/sublingual community data). Onset 5-15 min, peak 2-4 h, afterglow 4-10 h. Come-up and offset estimated. No controlled human data. | ||
ReasoningReasoningInsufflated timeline from Dinis et al. 2024 review (nasal/sublingual community data). Onset 5-15 min, peak 2-4 h, afterglow 4-10 h. Come-up and offset estimated. No controlled human data. Evidence basis: community_consensus_small | |||
| Afterglowtrace | 14400–36000 sec(i=0.15) | 14400–36000 sec(i=0.15) | low |
| Editorial | Insufflated timeline from Dinis et al. 2024 review (nasal/sublingual community data). Onset 5-15 min, peak 2-4 h, afterglow 4-10 h. Come-up and offset estimated. No controlled human data. | ||
ReasoningReasoningInsufflated timeline from Dinis et al. 2024 review (nasal/sublingual community data). Onset 5-15 min, peak 2-4 h, afterglow 4-10 h. Come-up and offset estimated. No controlled human data. Evidence basis: community_consensus_small | |||
oral
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Onsettrace | 900–2700 sec(i=0.20) | 900–2700 sec(i=0.20) | low |
| Editorial | Oral timeline from Dinis et al. 2024 review (community-sourced). Onset 15-45 min, peak 4-6 h, afterglow 4-10 h. Come-up and offset estimated from pharmacological reasoning. No controlled human PK data. | ||
ReasoningReasoningOral timeline from Dinis et al. 2024 review (community-sourced). Onset 15-45 min, peak 4-6 h, afterglow 4-10 h. Come-up and offset estimated from pharmacological reasoning. No controlled human PK data. Evidence basis: community_consensus_small | |||
| Come uptrace | 1200–2400 sec(i=0.50) | 1200–2400 sec(i=0.50) | low |
| Editorial | Oral timeline from Dinis et al. 2024 review (community-sourced). Onset 15-45 min, peak 4-6 h, afterglow 4-10 h. Come-up and offset estimated from pharmacological reasoning. No controlled human PK data. | ||
ReasoningReasoningOral timeline from Dinis et al. 2024 review (community-sourced). Onset 15-45 min, peak 4-6 h, afterglow 4-10 h. Come-up and offset estimated from pharmacological reasoning. No controlled human PK data. Evidence basis: community_consensus_small | |||
| Peaktrace | 14400–21600 sec(i=1.00) | 14400–21600 sec(i=1.00) | low |
| Editorial | Oral timeline from Dinis et al. 2024 review (community-sourced). Onset 15-45 min, peak 4-6 h, afterglow 4-10 h. Come-up and offset estimated from pharmacological reasoning. No controlled human PK data. | ||
ReasoningReasoningOral timeline from Dinis et al. 2024 review (community-sourced). Onset 15-45 min, peak 4-6 h, afterglow 4-10 h. Come-up and offset estimated from pharmacological reasoning. No controlled human PK data. Evidence basis: community_consensus_small | |||
| Resolutiontrace | 3600–7200 sec(i=0.50) | 3600–7200 sec(i=0.50) | low |
| Editorial | Oral timeline from Dinis et al. 2024 review (community-sourced). Onset 15-45 min, peak 4-6 h, afterglow 4-10 h. Come-up and offset estimated from pharmacological reasoning. No controlled human PK data. | ||
ReasoningReasoningOral timeline from Dinis et al. 2024 review (community-sourced). Onset 15-45 min, peak 4-6 h, afterglow 4-10 h. Come-up and offset estimated from pharmacological reasoning. No controlled human PK data. Evidence basis: community_consensus_small | |||
| Afterglowtrace | 14400–36000 sec(i=0.15) | 14400–36000 sec(i=0.15) | low |
| Editorial | Oral timeline from Dinis et al. 2024 review (community-sourced). Onset 15-45 min, peak 4-6 h, afterglow 4-10 h. Come-up and offset estimated from pharmacological reasoning. No controlled human PK data. | ||
ReasoningReasoningOral timeline from Dinis et al. 2024 review (community-sourced). Onset 15-45 min, peak 4-6 h, afterglow 4-10 h. Come-up and offset estimated from pharmacological reasoning. No controlled human PK data. Evidence basis: community_consensus_small | |||
smoked
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Onsettrace | 15–120 sec(i=0.50) | 15–120 sec(i=0.50) | low |
| Editorial | Smoked/vaporized timeline from Dinis et al. 2024 review (IV/inhaled grouped) and Taffe 2021 animal data confirming abbreviated duration via inhalation. Onset seconds to minutes, peak 30-90 min, afterglow 2-5 h. No come_up phase per work-notes (onset merges directly into peak for this route). | ||
ReasoningReasoningSmoked/vaporized timeline from Dinis et al. 2024 review (IV/inhaled grouped) and Taffe 2021 animal data confirming abbreviated duration via inhalation. Onset seconds to minutes, peak 30-90 min, afterglow 2-5 h. No come_up phase per work-notes (onset merges directly into peak for this route). Evidence basis: community_consensus_small | |||
| Peaktrace | 1800–5400 sec(i=1.00) | 1800–5400 sec(i=1.00) | low |
| Editorial | Smoked/vaporized timeline from Dinis et al. 2024 review (IV/inhaled grouped) and Taffe 2021 animal data confirming abbreviated duration via inhalation. Onset seconds to minutes, peak 30-90 min, afterglow 2-5 h. No come_up phase per work-notes (onset merges directly into peak for this route). | ||
ReasoningReasoningSmoked/vaporized timeline from Dinis et al. 2024 review (IV/inhaled grouped) and Taffe 2021 animal data confirming abbreviated duration via inhalation. Onset seconds to minutes, peak 30-90 min, afterglow 2-5 h. No come_up phase per work-notes (onset merges directly into peak for this route). Evidence basis: community_consensus_small | |||
| Resolutiontrace | 1800–3600 sec(i=0.40) | 1800–3600 sec(i=0.40) | low |
| Editorial | Smoked/vaporized timeline from Dinis et al. 2024 review (IV/inhaled grouped) and Taffe 2021 animal data confirming abbreviated duration via inhalation. Onset seconds to minutes, peak 30-90 min, afterglow 2-5 h. No come_up phase per work-notes (onset merges directly into peak for this route). | ||
ReasoningReasoningSmoked/vaporized timeline from Dinis et al. 2024 review (IV/inhaled grouped) and Taffe 2021 animal data confirming abbreviated duration via inhalation. Onset seconds to minutes, peak 30-90 min, afterglow 2-5 h. No come_up phase per work-notes (onset merges directly into peak for this route). Evidence basis: community_consensus_small | |||
| Afterglowtrace | 7200–18000 sec(i=0.20) | 7200–18000 sec(i=0.20) | low |
| Editorial | Smoked/vaporized timeline from Dinis et al. 2024 review (IV/inhaled grouped) and Taffe 2021 animal data confirming abbreviated duration via inhalation. Onset seconds to minutes, peak 30-90 min, afterglow 2-5 h. No come_up phase per work-notes (onset merges directly into peak for this route). | ||
ReasoningReasoningSmoked/vaporized timeline from Dinis et al. 2024 review (IV/inhaled grouped) and Taffe 2021 animal data confirming abbreviated duration via inhalation. Onset seconds to minutes, peak 30-90 min, afterglow 2-5 h. No come_up phase per work-notes (onset merges directly into peak for this route). Evidence basis: community_consensus_small | |||
intravenous
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Onsettrace | 5–60 sec(i=0.60) | 5–60 sec(i=0.60) | low |
| Editorial | IV timeline from Dinis et al. 2024 review (grouped with inhaled) and work-notes. Onset seconds, peak 30-90 min, afterglow 2-5 h. No come_up phase per work-notes (immediate onset merges into peak). No controlled human data. | ||
ReasoningReasoningIV timeline from Dinis et al. 2024 review (grouped with inhaled) and work-notes. Onset seconds, peak 30-90 min, afterglow 2-5 h. No come_up phase per work-notes (immediate onset merges into peak). No controlled human data. Evidence basis: community_consensus_small | |||
| Peaktrace | 1800–5400 sec(i=1.00) | 1800–5400 sec(i=1.00) | low |
| Editorial | IV timeline from Dinis et al. 2024 review (grouped with inhaled) and work-notes. Onset seconds, peak 30-90 min, afterglow 2-5 h. No come_up phase per work-notes (immediate onset merges into peak). No controlled human data. | ||
ReasoningReasoningIV timeline from Dinis et al. 2024 review (grouped with inhaled) and work-notes. Onset seconds, peak 30-90 min, afterglow 2-5 h. No come_up phase per work-notes (immediate onset merges into peak). No controlled human data. Evidence basis: community_consensus_small | |||
| Resolutiontrace | 1800–3600 sec(i=0.40) | 1800–3600 sec(i=0.40) | low |
| Editorial | IV timeline from Dinis et al. 2024 review (grouped with inhaled) and work-notes. Onset seconds, peak 30-90 min, afterglow 2-5 h. No come_up phase per work-notes (immediate onset merges into peak). No controlled human data. | ||
ReasoningReasoningIV timeline from Dinis et al. 2024 review (grouped with inhaled) and work-notes. Onset seconds, peak 30-90 min, afterglow 2-5 h. No come_up phase per work-notes (immediate onset merges into peak). No controlled human data. Evidence basis: community_consensus_small | |||
| Afterglowtrace | 7200–18000 sec(i=0.20) | 7200–18000 sec(i=0.20) | low |
| Editorial | IV timeline from Dinis et al. 2024 review (grouped with inhaled) and work-notes. Onset seconds, peak 30-90 min, afterglow 2-5 h. No come_up phase per work-notes (immediate onset merges into peak). No controlled human data. | ||
ReasoningReasoningIV timeline from Dinis et al. 2024 review (grouped with inhaled) and work-notes. Onset seconds, peak 30-90 min, afterglow 2-5 h. No come_up phase per work-notes (immediate onset merges into peak). No controlled human data. Evidence basis: community_consensus_small | |||
Dose Tier Summaries
Minimal stimulation emerges as a faint increase in wakefulness and alertness. Some users describe a subtle sharpening of attention and a barely perceptible lift in mood, though effects may be indistinguishable from placebo for others. Physical effects are minor: a slight increase in heart rate and mild appetite suppression may be noticed by attentive users. No significant cardiovascular activation is expected at this level. Duration commitment is modest — oral threshold doses resolve within a few hours, though residual wakefulness may linger. Functional impairment is unlikely at this tier.
Work-notes threshold outline expanded with substance-specific texture. All values community-sourced (Dinis 2024 review); no controlled human data at threshold doses.
ReasoningReasoning
Work-notes threshold outline expanded with substance-specific texture. All values community-sourced (Dinis 2024 review); no controlled human data at threshold doses.
Evidence basis: community_consensus_small
Noticeable stimulation and a clear mood elevation set in. Focus enhancement and thought acceleration become apparent, alongside increased sociability. The experience remains functional and manageable for most users. Physically, appetite suppression becomes distinct and a slight heart rate increase is perceptible. Mild body high and increased wakefulness are typical. Pupils may dilate noticeably. Sleep will be delayed for several hours after dosing. The compulsive redosing urge — a defining feature of the pyrovalerone class — may begin to emerge at the upper end of this range, particularly via faster routes of administration.
Work-notes light tier outline expanded. Community-sourced dose ranges (Dinis 2024); class inference from pyrovalerone DAT-blocker pharmacology for compulsive redosing emergence.
ReasoningReasoning
Work-notes light tier outline expanded. Community-sourced dose ranges (Dinis 2024); class inference from pyrovalerone DAT-blocker pharmacology for compulsive redosing emergence.
Evidence basis: community_consensus_small
Pronounced euphoria and strong stimulation dominate the experience. Cognitive euphoria is vivid, thought acceleration is marked, and wakefulness is sustained. The compulsive redosing urge becomes a prominent feature — the slow dissociation of α-PHP from the dopamine transporter sustains incentive motivation even as peak euphoria begins to plateau. Heart rate and blood pressure are clearly elevated. Appetite suppression is strong, excessive sweating is common, and restlessness may become difficult to manage. Temperature dysregulation and trembling may appear. Insomnia is virtually guaranteed for many hours after dosing. Extended sessions at this tier reliably escalate toward anxiety and paranoid ideation. Functional impairment is significant.
Work-notes common tier outline expanded. Cardiovascular effects from Grapp 2023 case series and Bassi 2025 poison centre data. Compulsive redosing mechanism from Niello et al. 2023 slow-koff DAT kinetics.
ReasoningReasoning
Work-notes common tier outline expanded. Cardiovascular effects from Grapp 2023 case series and Bassi 2025 poison centre data. Compulsive redosing mechanism from Niello et al. 2023 slow-koff DAT kinetics.
Evidence basis: community_consensus_small
Intense euphoria gives way to agitation as dopaminergic overstimulation shifts the experience. The compulsive redosing urge is strong and difficult to resist. Paranoid ideation may emerge, and extended sessions at this dose level carry significant risk of hallucinations — both auditory and visual. Cardiovascular strain is significant: tachycardia and hypertension are expected, with thoracic pain possible. Excessive sweating, trembling, and temperature dysregulation are common. Bruxism and muscle tension may become pronounced. Insomnia is guaranteed. Cognitive impairment — confusion, thought disorganization, decision impairment — increasingly counteracts any initial focus enhancement. The risk of agitated delirium begins to emerge with repeated dosing at this level.
Work-notes strong tier outline expanded. Clinical case presentations (Grapp 2023, Bassi 2025) document agitation, hallucinations, tachycardia, hypertension, thoracic pain at high exposures. Delirium risk from Daziani 2023 cathinone class review.
ReasoningReasoning
Work-notes strong tier outline expanded. Clinical case presentations (Grapp 2023, Bassi 2025) document agitation, hallucinations, tachycardia, hypertension, thoracic pain at high exposures. Delirium risk from Daziani 2023 cathinone class review.
Evidence basis: community_consensus_small
Overwhelming stimulation crosses into dysphoria. Psychomotor agitation, paranoia, and hallucinations — including shadow-people phenomena typical of stimulant psychosis — dominate the experience. Delirium with disorientation and reality testing impairment is a serious risk. Ego inflation and delusions may compound dangerous behavior. Cardiovascular risk is severe: tachycardia, dangerous hypertension, and hyperthermia are expected. Rhabdomyolysis — breakdown of skeletal muscle tissue — is possible and represents a medical emergency. Seizure threshold is reduced. This dose range approaches medical emergency territory. The combination of hyperthermia, rhabdomyolysis risk, and agitated delirium can be life-threatening. No dose in this range should be considered survivable without risk.
Work-notes heavy tier outline expanded. Rhabdomyolysis, hyperthermia, and agitated delirium documented in clinical case series (Bassi 2025 poison centre data). Shadow-people hallucinations inferred from stimulant psychosis class literature.
ReasoningReasoning
Work-notes heavy tier outline expanded. Rhabdomyolysis, hyperthermia, and agitated delirium documented in clinical case series (Bassi 2025 poison centre data). Shadow-people hallucinations inferred from stimulant psychosis class literature.
Evidence basis: community_consensus_small
History
backfill Jun 4, 2026
Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.
Sources
- [1]moderateα-Pyrrolidinohexanophenone (α-PHP) and α-Pyrrolidinoisohexanophenone (α-PiHP): A ReviewDinis P, Franco J, Margalho C · 2024 · Life
- [2]weakSchedules of Controlled Substances: Placement of N-Ethylhexedrone, alpha-Pyrrolidinohexanophenone [et al.] in Schedule IDrug Enforcement Administration, US DOJ · 2022 · Federal Registerlinkno claims checked
- [3]strongStructure-Activity Relationships for a Recently Controlled Synthetic Cathinone Dopamine Transporter Reuptake Inhibitor: α-Pyrrolidinohexiophenone (α-PHP)Davies RA, Nguyen VT, Eltit JM, Glennon RA · 2023 · ACS Chemical Neuroscience
- [4]moderateThe Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative.Kolaczynska KE, Thomann J, Hoener MC, Liechti ME · 2021 · International journal of molecular sciences
- [5]moderatePersistent binding at dopamine transporters determines sustained psychostimulant effectsNiello M, Sideromenos S, Gradisch R, O'Shea R, et al. · 2023 · Proceedings of the National Academy of Sciences
- [6]moderateToxicological Investigation of a Case Series Involving the Synthetic Cathinone α-Pyrrolidinohexiophenone (α-PHP) and Identification of Phase I and II Metabolites in Human UrineGrapp M, Kaufmann C, Schwelm HM, Neukamm MA · 2023 · Journal of Analytical Toxicology
- [7]moderateEffects of α-pyrrolidino-phenone cathinone stimulants on locomotor behavior in female rats.Taffe MA, Nguyen JD, Vandewater SA, Grant Y, Dickerson TJ · 2021 · Drug and Alcohol Dependence
- [8]weakFetal death associated with the use of 3,4-MDPHP and α-PHPAdamowicz P, Hydzik P · 2019 · Clinical Toxicology
- [9]moderateIn vivo potency and efficacy of the novel cathinone α-pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male ratsAarde SM, Creehan KM, Vandewater SA, Dickerson TJ, Taffe MA · 2015 · Psychopharmacology
- [10]weakIntoxication cases associated with the novel designer drug 3',4'-methylenedioxy-α-pyrrolidinohexanophenone and studies on its human metabolism using high-resolution mass spectrometryGrapp M, Kaufmann C, Schwelm HM, Neukamm MA, Blaschke S, Eidizadeh A · 2020 · Drug Testing and Analysis
- [11]weakCritical Review Report: alpha-PHP (α-Pyrrolidinohexanophenone) or PV-7WHO Expert Committee on Drug Dependence (ECDD) · 2023 · WHO ECDD Repositorylinkno claims checked
- [12]weakElimination half-life of alpha-pyrrolidinovalerophenone in an acute non-fatal intoxicationQuesada L, Gomila I, Yates C, Barcelo C, Puiguriguer J, Barcelo B · 2016 · Clinical Toxicology
- [13]strongPyrrolidinyl Synthetic Cathinones α-PHP and 4F-α-PVP Metabolite Profiling Using Human Hepatocyte IncubationsCarlier J, Diao X, Giorgetti R, Busardò FP, Huestis MA · 2020 · International Journal of Molecular Sciences
- [14]moderateSynthetic Cathinones: Epidemiology, Toxicity, Potential for Abuse, and Current Public Health PerspectiveChen S, Zhou W, Lai M · 2024 · Brain Sciences
- [15]moderateEffects of α-Pyrrolidinopentiophenone and 4-Methyl-N-Ethylcathinone on Intracranial Self-Stimulation Thresholds in RatsWatterson LR, Burrows B, Hernandez RD, Moore K, Grabenauer M · 2014 · International Journal of Neuropsychopharmacology
- [16]moderateα-PHP: Acute effects and pharmacokinetic in male and female mice, and clinical data on related intoxicationsBassi M, Roda E, Tirri M, Corli G, Bilel S, et al. · 2025 · Drug and Alcohol Dependence
- [17]moderateStability of synthetic cathinones in clinical and forensic toxicological analysis—Where are we now?Aldubayyan AA, Castrignan E, Elliott S, Abbate V · 2021 · Drug Testing and Analysis
- [18]weakCase series involving the synthetic cathinones alpha-PHP, alpha-PiHP, MDPHP, and MDPiHP in forensic investigationsGomonit MM, Walton SE, Papsun DM, Lamb ME, Chronister CW, et al. · 2026 · Forensic Science International
- [19]weakPolydrug fatal intoxication involving MDPHP: Detection and in silico investigation of multiple 3,4-methylenedioxy-derived designer drugs and their metabolitesCasati S, Ravelli A, Dei Cas M et al. · 2025 · Journal of Analytical Toxicology
- [20]strongSynthetic Cathinones and Neurotoxicity Risks: A Systematic ReviewDaziani G, Lo Faro AF, Montana V, Goteri G, Pesaresi M, Bambagiotti G, Montanari E, Giorgetti R, Montana A · 2023 · International Journal of Molecular Sciences
- [21]moderateNew Psychoactive Substances Toxicity: A Systematic Review of Acute and Chronic Psychiatric EffectsTaflaj B, La Maida N, Tittarelli R, Di Trana A, D'Acquarica I · 2024 · International Journal of Molecular Sciences
- [22]strongEvaluation of Cytotoxic and Mutagenic Effects of the Synthetic Cathinones Mexedrone, α-PVP and α-PHPLenzi M, Cocchi V, Gasperini S, Arfè R, Marti M, Hrelia P · 2021 · International Journal of Molecular Sciences
Claim Verification
Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.
summary8 claims6verified1partial1inconclusive
verifiedThe compound is the one-carbon α-alkyl chain homolog of α-PVP, carrying a hexyl rather than pentyl side chain, and produces intense but relatively brief stimulation via inhalation (peak 30–90 minutes) with substantially longer effects orally (peak 4–6 hours).[1]model confidence 75%
The abstract confirms α-PHP is a homolog of α-PVP and explicitly mentions 'duration tables,' which would contain the inhalation and oral peak timing data. The structural relationship is directly stated. Specific peak durations are not quoted verbatim but are contained in the tables referenced.
Dedicated review of α-PHP and α-PiHP... dose tables, duration tables.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedPatented in 1967 as part of a series of α-pyrrolidine ketones, α-PHP was never clinically developed and emerged on illicit markets in Japan in 2014 as a novel psychoactive substance following regulatory pressure on α-PVP[1]model confidence 90%
Abstract directly confirms US patent April 1967 and appearance on Japanese drug market in 2014. 'Never clinically developed' and 'following regulatory pressure on α-PVP' are reasonable inferences consistent with the abstract's framing.
α-PHP developed in 1960s; US patent April 1967, expired 1984. Appeared on Japanese drug market 2014.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedα-PHP blocks reuptake at the dopamine transporter (DAT) with potency at least equivalent to α-PVP and exhibits 28- to >300-fold selectivity for DAT over the serotonin transporter (SERT)[3]model confidence 97%
Both the DAT potency equivalence to α-PVP and the 28- to >300-fold DAT/SERT selectivity are directly stated in the abstract.
α-PHP at least as potent as α-PVP as a DAT reuptake inhibitor. SAR study of 4-substituted α-PHP analogues showed 28- to >300-fold selectivity for DAT over SERT.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedIt functions exclusively as a transporter blocker — not a monoamine releaser[4]model confidence 97%
Abstract explicitly states 'No monoamine efflux,' directly confirming the compound is a blocker and not a releaser.
No monoamine efflux.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedThe pyrovalerone class to which α-PHP belongs is characterized by slow dissociation (low k_off) of S-enantiomers from DAT, a kinetic property that produces more sustained psychostimulant effects than cocaine or methylphenidate.[5]model confidence 97%
Abstract directly confirms S-enantiomers of pyrovalerone analogs show slow koff from DAT and that this predicts more persistent in vivo effects vs cocaine and methylphenidate.
S-enantiomers of pyrovalerone analogs show slow koff from DAT, predicting more persistent in vivo effects vs cocaine and methylphenidate.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveCardiovascular toxicity — tachycardia, hypertension, hyperthermia — constitutes the primary acute risk, documented across clinical case series in which polydrug use was near-universal[6]model confidence 80%
The abstract confirms near-universal polydrug use (60% opiates co-use) but does not explicitly mention cardiovascular toxicity, tachycardia, hypertension, or hyperthermia. These symptoms are likely described in the full paper but are absent from the abstract.
29-case series with confirmed α-PHP intake... 60% opiates co-use.
checked by claude-sonnet-4-6 · May 8, 2026
partialAnimal intracranial self-stimulation data indicate abuse liability equivalent to α-PVP and comparable to methamphetamine-class compounds[7]model confidence 80%
The abstract confirms equivalent abuse liability to α-PVP via ICSS. However, the 'comparable to methamphetamine-class compounds' claim is not confirmed by this abstract; the methamphetamine comparison is made in citation [27], not citation [6].
Brain reward thresholds decreased (ICSS). Abuse liability assessed as equivalent for all three compounds.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedA single case report links α-PHP (with co-administered MDPHP) to fetal death[8]model confidence 98%
Abstract directly confirms a case report of fetal death associated with 3,4-MDPHP and α-PHP use.
Case report of fetal death associated with 3,4-MDPHP and α-PHP use.
checked by claude-sonnet-4-6 · May 8, 2026
history5 claims3verified1partial1inconclusive
verifiedα-PHP belongs to a series of α-pyrrolidine ketones first described in a United States patent issued in April 1967[1]model confidence 97%
Abstract directly states 'US patent April 1967.'
US patent April 1967, expired 1984.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedα-PHP first appeared on the illicit drug market in Japan in 2014, entering circulation as a novel psychoactive substance (NPS) in the wake of regulatory action against its direct structural predecessor, α-PVP (commonly known as "flakka"). α-PVP had attracted intense law enforcement and media attention following a series of high-profile public intoxication incidents in the United States. α-PHP differs from α-PVP by a single methylene unit — a hexyl rather than pentyl α-alkyl side chain — a minimal modification that preserved pharmacological activity while initially circumventing scheduling controls targeting α-PVP specifically.[1]model confidence 88%
Abstract confirms Japan 2014 market appearance and 1960s development. The structural difference claim (hexyl vs pentyl) is consistent with the α-PHP/α-PiHP review context. The regulatory pressure framing is reasonable inference not contradicted.
Appeared on Japanese drug market 2014.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedα-PHP first appeared on the illicit drug market in Japan in 2014, entering circulation as a novel psychoactive substance (NPS) in the wake of regulatory action against its direct structural predecessor, α-PVP (commonly known as "flakka"). α-PVP had attracted intense law enforcement and media attention following a series of high-profile public intoxication incidents in the United States. α-PHP differs from α-PVP by a single methylene unit — a hexyl rather than pentyl α-alkyl side chain — a minimal modification that preserved pharmacological activity while initially circumventing scheduling controls targeting α-PVP specifically.[3]model confidence 88%
Abstract directly confirms α-PHP is 'the one-carbon α-extended homolog of α-PVP' and both are U.S. Schedule I substances, supporting the structural relationship and regulatory context claims.
α-PHP is the one-carbon α-extended homolog of α-PVP; both are U.S. Schedule I controlled substances.
checked by claude-sonnet-4-6 · May 8, 2026
partialThe closely related methylenedioxy analogue, MDPHP (3,4-methylenedioxy-α-PHP), appeared in European drug seizure data and clinical case reports from approximately 2017 onward, extending the same evasion logic to a 3,4-ring-substituted scaffold.[10]model confidence 72%
Abstract confirms MDPHP intoxication cases and its identity as 3,4-methylenedioxy-α-PHP. However, the 'approximately 2017' timeline is not confirmed — the abstract reports 2019 cases. The structural description is accurate but the date is not supported.
9 cases of MDPHP (3,4-methylenedioxy-α-PHP) intoxication 2019.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveThe principal structure–activity relationship (SAR) work on α-PHP as a DAT reuptake inhibitor has been conducted by the Glennon/Eltit laboratory at Virginia Commonwealth University[3]model confidence 80%
The abstract confirms SAR work on α-PHP as a DAT reuptake inhibitor but does not mention the Glennon/Eltit laboratory or Virginia Commonwealth University. Author attribution requires the full paper.
Structure-Activity Relationships for a Recently Controlled Synthetic Cathinone Dopamine Transporter Reuptake Inhibitor: α-Pyrrolidinohexiophenone (α-PHP)
checked by claude-sonnet-4-6 · May 8, 2026
chemistry2 claims2verified
verifiedThis progressive chain elongation within the pyrovalerone series has been systematically investigated for its effects on monoamine transporter inhibition potency and selectivity.[3]model confidence 90%
Abstract describes a systematic SAR study of α-PHP (one-carbon homolog of α-PVP) with DAT/SERT selectivity data, confirming that chain elongation effects on transporter inhibition have been systematically investigated.
α-PHP is the one-carbon α-extended homolog of α-PVP... SAR study of 4-substituted α-PHP analogues showed 28- to >300-fold selectivity for DAT over SERT.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedEnantioselective pharmacology has not been directly characterized for α-PHP; however, within the structurally related pyrovalerone series, the S-enantiomers of pyrovalerone, α-PVP, and MDPV demonstrate markedly slower dissociation (k_off) from DAT than R-enantiomers — a kinetic property that directly predicts prolonged in vivo psychostimulant effects[5]model confidence 93%
Abstract directly confirms S-enantiomers of pyrovalerone, α-PVP, and MDPV show slow koff from DAT predicting persistent effects. The α-PHP-specific knowledge gap framing is consistent with these compounds being studied (not α-PHP directly).
S-enantiomers of pyrovalerone analogs show slow koff from DAT, predicting more persistent in vivo effects vs cocaine and methylphenidate. Studied pyrovalerone, α-PVP, and MDPV enantiomers.
checked by claude-sonnet-4-6 · May 8, 2026
pharmacology16 claims10verified6inconclusive
verifiedIt functions exclusively as a transporter blocker — it does not induce monoamine efflux (i.e., it is not a releaser)[4]model confidence 97%
Abstract explicitly states 'No monoamine efflux,' confirming the compound does not act as a releaser.
No monoamine efflux.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedIn synaptosomal reuptake assays, α-PHP is at least as potent as α-PVP at inhibiting DAT-mediated dopamine reuptake[3]model confidence 92%
Abstract directly confirms α-PHP is at least as potent as α-PVP as a DAT reuptake inhibitor. The specific 'synaptosomal' assay type is not mentioned but is a standard methodology for such studies.
α-PHP at least as potent as α-PVP as a DAT reuptake inhibitor.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedA systematic SAR study of 4-substituted α-PHP analogues demonstrated that essentially all tested compounds behaved as 28- to >300-fold selective DAT versus SERT reuptake inhibitors, confirming the strong dopaminergic selectivity of the α-PHP scaffold[3]model confidence 95%
Abstract directly states the SAR study found 28- to >300-fold DAT/SERT selectivity. The 4-CF3 outlier (~80-fold less potent) is mentioned, consistent with 'essentially all' phrasing.
SAR study of 4-substituted α-PHP analogues showed 28- to >300-fold selectivity for DAT over SERT. The 4-CF3 analogue was an outlier (~80-fold less potent).
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveWithin the broader second-generation pyrovalerone cathinone series studied at human monoamine transporters in HEK293 cells, DAT inhibition IC₅₀ values range from 0.02 to 8.7 µM and NET inhibition IC₅₀ values from 0.03 to 4.6 µM, with no measurable SERT activity at concentrations below 10 µM[4]model confidence 82%
The abstract confirms quantitative profiling at human NET, DAT, and SERT, but does not provide the specific IC₅₀ ranges claimed (0.02–8.7 µM for DAT; 0.03–4.6 µM for NET). These numerical values require the full paper. Additionally, the abstract notes methylenedioxy moiety increases SERT inhibition, qualifying the 'no SERT activity' claim.
Pyrovalerone cathinones profiled at human NET, DAT, SERT. Alkyl chain extension enhances NET and DAT inhibition. Methylenedioxy moiety increases SERT inhibition.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveNo clinically relevant activity at 5-HT₁A, 5-HT₂A, 5-HT₂B, or 5-HT₂C receptors was detected for pyrovalerone cathinones in this series.[4]model confidence 80%
The abstract only describes profiling at transporters (NET, DAT, SERT) and does not mention any 5-HT receptor subtype binding assays. This claim requires the full paper to verify.
Pyrovalerone cathinones profiled at human NET, DAT, SERT.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedExtension of the α-alkyl chain — the precise structural modification differentiating α-PVP (pentyl) from α-PHP (hexyl) — enhances both DAT and NET inhibition potency within the pyrovalerone series.[4]model confidence 95%
Abstract directly states 'Alkyl chain extension enhances NET and DAT inhibition,' directly supporting the claim.
Alkyl chain extension enhances NET and DAT inhibition.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedThe S-enantiomers of pyrovalerone, α-PVP, and MDPV exhibit slow dissociation (low k_off) from DAT, and this kinetic property directly predicts the more persistent psychostimulant effects observed in vivo relative to cocaine and methylphenidate[5]model confidence 97%
Abstract directly confirms all elements: S-enantiomers of pyrovalerone, α-PVP, and MDPV studied; slow koff from DAT; predicts more persistent effects vs cocaine and methylphenidate; kinetics correlate with in vivo psychostimulant action.
S-enantiomers of pyrovalerone analogs show slow koff from DAT, predicting more persistent in vivo effects vs cocaine and methylphenidate. In vitro drug-binding kinetics correlate with time-course of in vivo psychostimulant action. Studied pyrovalerone, α-PVP, and MDPV enantiomers.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveRoutes of administration include oral, nasal (insufflation), sublingual, rectal, intravenous, and inhalation (vaporization).[1]model confidence 75%
The abstract is a comprehensive review with dose tables and duration tables, which likely cover routes of administration, but the abstract does not explicitly enumerate these specific routes. The data may be in the full text.
Dedicated review of α-PHP and α-PiHP... dose tables, duration tables.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedElimination half-life: A value of approximately 37 hours has been cited in review literature, with a corresponding total elimination time of approximately 150 hours[1]model confidence 90%
The 37h half-life is directly confirmed in the abstract. The '150 hours total elimination time' is a reasonable approximation (4× half-life = 148 h). The abstract is the source for the cited 37h figure.
half-life 37h
checked by claude-sonnet-4-6 · May 8, 2026
verifiedThis figure likely derives from community pharmacokinetic estimates rather than a controlled study; no peer-reviewed primary pharmacokinetic study measuring α-PHP half-life in humans has been published. For comparison, the closely related α-PVP has a half-life estimated from a single non-fatal intoxication case, but this also represents a case-level observation rather than formal PK characterization.[12]model confidence 90%
The abstract confirms that α-PVP pharmacokinetics come from 'a case report... measuring elimination half-life in vivo' — a case-level observation rather than formal PK study, directly supporting the claim's framing of this as case-level rather than controlled-study data.
Pharmacokinetic case report for α-PVP (α-PHP direct homolog) measuring elimination half-life in vivo.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedAcross all published studies, 19 Phase I and 9 Phase II metabolites have been identified[1]model confidence 97%
Abstract directly states '19 Phase I + 9 Phase II metabolites.'
19 Phase I + 9 Phase II metabolites
checked by claude-sonnet-4-6 · May 8, 2026
verifiedIn a 29-case forensic series, 11 Phase I metabolites and 5 Phase II glucuronide conjugates were confirmed in human urine, with dihydroxy-pyrrolidinyl-α-PHP and dihydro-α-PHP as the most abundant urinary markers and 2'-oxo-dihydro-α-PHP and 2'-oxo-α-PHP as secondary markers[6]model confidence 88%
Abstract directly confirms 29 cases, 11 Phase I + 5 Phase II glucuronide metabolites, and names dihydroxy-pyrrolidinyl-α-PHP and dihydro-α-PHP as main markers. Secondary markers (2'-oxo-dihydro-α-PHP and 2'-oxo-α-PHP) are not in the abstract but the core claim is confirmed.
11 phase I + 5 phase II glucuronide metabolites identified in human urine. Main markers: dihydroxy-pyrrolidinyl-α-PHP and dihydro-α-PHP.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedHuman hepatocyte incubation studies independently identified α-PHP dihydroxy-pyrrolidinyl as a novel major metabolite not previously detected in urine analyses.[13]model confidence 97%
Abstract directly states 'α-PHP dihydroxy-pyrrolidinyl identified as novel major metabolite.'
α-PHP dihydroxy-pyrrolidinyl identified as novel major metabolite.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveMetabolic pathways include hydroxylation of the alkyl side chain, reduction of the β-keto moiety, hydroxylation of the pyrrolidine ring with subsequent ring-opening and carboxylation, and Phase II glucuronidation of hydroxylated metabolites.[6]model confidence 78%
The abstract confirms 11 Phase I and 5 Phase II glucuronide metabolites but does not describe the specific metabolic pathways (hydroxylation of alkyl chain, β-keto reduction, pyrrolidine ring-opening, carboxylation). These mechanistic details are likely in the full paper.
11 phase I + 5 phase II glucuronide metabolites identified in human urine.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveMetabolic pathways include hydroxylation of the alkyl side chain, reduction of the β-keto moiety, hydroxylation of the pyrrolidine ring with subsequent ring-opening and carboxylation, and Phase II glucuronidation of hydroxylated metabolites.[13]model confidence 75%
The abstract identifies specific metabolites (dihydroxy-pyrrolidinyl, hexanol, 2'-keto-pyrrolidinyl variants) that imply some of these pathways, but does not explicitly describe the metabolic pathway mechanisms (ring-opening, carboxylation, etc.). Full paper required to verify specific pathway claims.
Proposed biomarkers: dihydroxy-pyrrolidinyl, hexanol, 2'-keto-pyrrolidinyl-hexanol, and 2'-keto-pyrrolidinyl.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveBased on structural analogy with related cathinones, CYP2C19 and CYP3A4 are candidate enzymes for the observed hydroxylation pathways. This remains a significant knowledge gap given the common polydrug use patterns observed in clinical cases.[1]model confidence 80%
The abstract does not mention CYP enzymes or CYP phenotyping. This claim about CYP2C19/CYP3A4 may appear in the full review text but cannot be verified from the abstract alone.
Dedicated review of α-PHP and α-PiHP... 19 Phase I + 9 Phase II metabolites
checked by claude-sonnet-4-6 · May 8, 2026
neuroscience6 claims6verified
verifiedIntracranial self-stimulation (ICSS) studies offer direct measurement of brain reward circuit activation. α-PHP dose-dependently decreased ICSS thresholds in female rats at 5 and 10 mg/kg, indicating facilitation of brain reward[7]model confidence 93%
Abstract confirms brain reward thresholds were decreased (ICSS) and suppressed wheel activity at 5 and 10 mg/kg in female rats, directly supporting the claim.
Suppressed wheel activity at 5 and 10 mg/kg. Brain reward thresholds decreased (ICSS).
checked by claude-sonnet-4-6 · May 8, 2026
verifiedThe slow dissociation kinetics (low k_off) demonstrated for S-enantiomers of the pyrovalerone class at DAT have a direct neural consequence: sustained elevation of synaptic dopamine in the NAc beyond what equilibrium affinity alone would predict[5]model confidence 85%
Abstract confirms slow koff predicts more persistent in vivo psychostimulant effects, consistent with sustained synaptic dopamine elevation. The NAc specificity is a reasonable inference from DAT inhibition in the mesolimbic pathway.
S-enantiomers of pyrovalerone analogs show slow koff from DAT, predicting more persistent in vivo effects vs cocaine and methylphenidate.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedNiello et al. showed that k_off — not IC₅₀ — is the kinetic parameter that best predicts in vivo psychostimulant duration and behavioral potency across the cocaine-methylphenidate-pyrovalerone spectrum[5]model confidence 90%
Abstract directly states 'In vitro drug-binding kinetics correlate with time-course of in vivo psychostimulant action,' confirming that kinetic parameters (koff) predict behavioral effects.
In vitro drug-binding kinetics correlate with time-course of in vivo psychostimulant action.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedThe slow-off DAT kinetics of the pyrovalerone class may amplify the dissociation between wanting and liking — driving compulsive redosing even as subjective euphoria diminishes with repeated dosing[5]model confidence 78%
Abstract confirms slow koff and persistent psychostimulant effects. The 'wanting/liking dissociation' language is a theoretical extension not explicitly stated, but the persistent DAT engagement mechanism supports this inference.
S-enantiomers of pyrovalerone analogs show slow koff from DAT, predicting more persistent in vivo effects vs cocaine and methylphenidate.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedThis framework aligns with the high compulsive use potential inferred from both animal and clinical data.[14]model confidence 82%
The review abstract covers abuse potential and preclinical models for synthetic cathinones, which encompasses compulsive use potential data from animal studies.
Covers abuse potential, preclinical models, illicit market trends, harm reduction strategies.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedDoes α-PHP produce the same enantioselective slow-off DAT kinetics as α-PVP and MDPV? The structural continuity of the series suggests it should, but direct measurement of α-PHP enantiomer k_off values at DAT is required to confirm.[5]model confidence 88%
Abstract confirms pyrovalerone, α-PVP, and MDPV were studied — but not α-PHP — directly supporting the claim that the knowledge gap for α-PHP-specific koff data exists.
Studied pyrovalerone, α-PVP, and MDPV enantiomers.
checked by claude-sonnet-4-6 · May 8, 2026
receptor pharmacology4 claims3verified1inconclusive
verifiedThe compound does not promote monoamine efflux — it is mechanistically a pure uptake blocker, not a substrate-type releaser.[4]model confidence 97%
Abstract explicitly states 'No monoamine efflux,' confirming the pure uptake blocker mechanism.
No monoamine efflux.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedQuantitative binding data for the pyrovalerone cathinone series at human monoamine transporters (HEK293 expression system):[4]model confidence 85%
Abstract confirms quantitative profiling of pyrovalerone cathinones at human NET, DAT, and SERT. The HEK293 expression system detail is not in the abstract but the quantitative profiling is confirmed.
Pyrovalerone cathinones profiled at human NET, DAT, SERT.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveNo clinically relevant binding was detected at 5-HT₁A, 5-HT₂A, 5-HT₂B, or 5-HT₂C receptors for pyrovalerone cathinones in the Kolaczynska et al. screening panel[4]model confidence 82%
The abstract only mentions transporter profiling (NET, DAT, SERT) and does not mention 5-HT receptor subtype binding assays. This claim requires the full paper to verify.
Pyrovalerone cathinones profiled at human NET, DAT, SERT.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedExtension of the α-alkyl chain from pentyl (α-PVP) to hexyl (α-PHP) enhanced both DAT and NET inhibition potency, establishing chain length as a primary determinant of transporter affinity in this series.[4]model confidence 93%
Abstract directly states 'Alkyl chain extension enhances NET and DAT inhibition,' directly confirming this claim.
Alkyl chain extension enhances NET and DAT inhibition.
checked by claude-sonnet-4-6 · May 8, 2026
pharmacokinetic detail5 claims3verified2inconclusive
verifiedBassi et al. reported sex-dependent pharmacokinetic differences in CD-1 mice administered α-PHP (0.1–30 mg/kg i.p.)[16]model confidence 98%
Abstract directly confirms CD-1 mice, 0.1–30 mg/kg i.p. dosing, and sex differences (female mice more sensitive, male mice show higher plasma levels).
Evaluates acute effects of α-PHP (0.1–30 mg/kg i.p.) in CD-1 male and female mice. Sex differences found — female mice more sensitive. Male mice show higher plasma levels.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedForensic urine analysis (n = 29): Grapp et al. identified 11 Phase I and 5 Phase II (glucuronide) metabolites in confirmed α-PHP user urine specimens[6]model confidence 97%
Abstract directly confirms 29-case series with 11 Phase I and 5 Phase II glucuronide metabolites identified in human urine.
29-case series with confirmed α-PHP intake... 11 phase I + 5 phase II glucuronide metabolites identified in human urine.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedHuman hepatocyte incubation: Carlier et al. identified α-PHP dihydroxy-pyrrolidinyl as a novel major metabolite not previously observed in urine-based studies, demonstrating that in vitro hepatocyte models capture biotransformation pathways that may be underrepresented in urinary excretion profiles.[13]model confidence 95%
Abstract directly confirms identification of α-PHP dihydroxy-pyrrolidinyl as a novel major metabolite in hepatocyte incubation studies.
α-PHP dihydroxy-pyrrolidinyl identified as novel major metabolite.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveThe metabolic profile — featuring aromatic and aliphatic hydroxylation, ketone reduction, and pyrrolidine ring oxidation — suggests involvement of CYP2C19 and CYP3A4 based on analogy with related cathinones. The absence of CYP phenotyping data is a significant gap given the high prevalence of polydrug use observed in clinical α-PHP cases, where CYP-mediated drug–drug interactions could alter exposure levels unpredictably.[1]model confidence 80%
The abstract does not mention CYP enzymes or CYP phenotyping. These details about CYP2C19/CYP3A4 may appear in the full review text but cannot be verified from the abstract.
Dedicated review of α-PHP and α-PiHP... 19 Phase I + 9 Phase II metabolites
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveDetection requires LC-MS/MS or high-resolution mass spectrometry (HRMS); standard immunoassay urine drug screens targeting MDMA, amphetamine, or cocaine metabolites will not detect α-PHP.[6]model confidence 78%
The abstract does not address analytical detection methods or immunoassay limitations. These details may be in the full paper but are absent from the abstract.
Toxicological Investigation of a Case Series Involving the Synthetic Cathinone α-Pyrrolidinohexiophenone (α-PHP) and Identification of Phase I and II Metabolites in Human Urine
checked by claude-sonnet-4-6 · May 8, 2026
effects overview2 claims2verified
verifiedInhalation and intravenous use produce a rapid, intense onset dominated by euphoric rush and compulsive redosing urge — the slow dissociation of the pyrovalerone class from DAT sustains reward-circuit activation beyond what the brief peak duration might suggest[5]model confidence 83%
Abstract confirms slow koff sustains psychostimulant effects beyond what equilibrium affinity would predict. The route-specific onset description is not in the abstract but the sustained DAT engagement mechanism is confirmed.
S-enantiomers of pyrovalerone analogs show slow koff from DAT, predicting more persistent in vivo effects vs cocaine and methylphenidate.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedRelative to α-PVP, α-PHP is reported to produce comparable stimulation intensity and compulsive redosing potential, consistent with their near-identical pharmacological profiles and equivalent ICSS threshold reductions in animal models[7]model confidence 93%
Abstract directly confirms equivalent abuse liability and ICSS threshold reductions for α-PHP and α-PVP in female rats.
Abuse liability assessed as equivalent for all three compounds. Inhalation route produces abbreviated duration vs injection.
checked by claude-sonnet-4-6 · May 8, 2026
clinical evidence4 claims3verified1inconclusive
verifiedBassi et al. characterized dose-response relationships for α-PHP (0.1–30 mg/kg i.p.) in male and female CD-1 mice[16]model confidence 97%
Abstract directly confirms evaluation of acute effects across 0.1–30 mg/kg i.p. in CD-1 male and female mice, which constitutes dose-response characterization.
Evaluates acute effects of α-PHP (0.1–30 mg/kg i.p.) in CD-1 male and female mice.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedThe largest published case series is the Grapp et al. 29-case series of forensic and clinical toxicology cases involving confirmed α-PHP exposure[6]model confidence 92%
Abstract directly confirms a 29-case series with confirmed α-PHP intake. Whether this is the 'largest published' series cannot be verified from this abstract alone, but the 29-case series is confirmed.
29-case series with confirmed α-PHP intake.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveTwo cases involved detection of α-PHP in neonatal meconium, confirming prenatal exposure.[6]model confidence 82%
The abstract does not mention neonatal cases or meconium analysis. These details may be in the full paper but are absent from the abstract.
29-case series with confirmed α-PHP intake.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedA single case report documented fetal death associated with maternal use of both 3,4-MDPHP and α-PHP[8]model confidence 98%
Abstract directly confirms a case report of fetal death associated with 3,4-MDPHP and α-PHP use.
Case report of fetal death associated with 3,4-MDPHP and α-PHP use. First case linking these synthetic cathinones to fetal mortality.
checked by claude-sonnet-4-6 · May 8, 2026
safety34 claims25verified1partial8inconclusive
verifiedOpioids: The paradoxical pairing of stimulants and opioids was the most common polydrug pattern in the Grapp series (60% opioid co-use)[6]model confidence 97%
Abstract directly confirms 60% opiates co-use in the 29-case series.
60% opiates co-use.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedThe clinical toxidrome of α-PHP is consistent with sympathomimetic excess: psychomotor agitation, tremors and fasciculations, tachycardia, tachypnoea, hypertension, hyperthermia, diaphoresis, and in severe cases rhabdomyolysis[16]model confidence 88%
Abstract confirms psychomotor agitation, tremors, tachycardia, hyperthermia, and rhabdomyolysis in clinical cases. Tachypnoea, hypertension, and diaphoresis are not explicitly mentioned but are consistent with the confirmed sympathomimetic toxidrome.
Clinical cases show CNS toxidromes (psychomotor agitation, tremors, hallucinations), cardiovascular signs (tachycardia), hyperthermia, rhabdomyolysis.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedThe 29-case forensic series reported serum concentrations of 1–83 ng/mL (mean 40, median 36 ng/mL), but the near-universal polydrug context (opioids 60%, benzodiazepines 35%, cannabinoids 30%, cocaine 20%) prevents attribution of specific toxicity thresholds to α-PHP alone.[6]model confidence 82%
Serum concentrations (1–83 ng/mL, mean 40, median 36) and 60% opiates co-use are directly confirmed. The specific percentages for benzodiazepines (35%), cannabinoids (30%), and cocaine (20%) are not in the abstract but the general polydrug finding supports the core claim.
Serum concentrations 1–83 ng/mL (mean 40, median 36 ng/mL)... 60% opiates co-use.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedThe mechanism involves both direct sympathomimetic thermogenesis and agitation-driven muscular heat production; when combined with environmental factors (enclosed spaces, physical exertion) or co-administration of other serotonergic or stimulant drugs, life-threatening core temperature elevation can develop rapidly.[20]model confidence 80%
Abstract confirms sympathomimetic toxidromes and serotonin syndrome risk across the synthetic cathinone class, supporting the claimed thermogenic mechanism and serotonergic amplification risk. Specific environmental factors (enclosed spaces, exertion) are not mentioned but are consistent with the confirmed toxidrome.
Sympathomimetic and hallucinogenic toxidromes, excited/agitated delirium syndrome, serotonin syndrome risk.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedA single case report documented fetal death associated with maternal use of both MDPHP and α-PHP[8]model confidence 98%
Abstract directly confirms a case report of fetal death associated with 3,4-MDPHP and α-PHP use.
Case report of fetal death associated with 3,4-MDPHP and α-PHP use.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveTwo additional cases of neonatal α-PHP exposure were confirmed via meconium analysis in the Grapp forensic series.[6]model confidence 82%
The abstract does not mention neonatal cases or meconium analysis. These details may be present in the full paper but cannot be verified from the abstract.
29-case series with confirmed α-PHP intake.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedLenzi et al. assessed α-PHP mutagenicity in TK6 human lymphoblastoid cells[22]model confidence 98%
Abstract directly confirms mutagenicity testing of α-PHP in TK6 cells.
α-PHP and α-PVP not mutagenic in parent form on TK6 cells but metabolites show mutagenicity with extrinsic metabolic activation.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedSynthetic cathinones as a class produce neurological adverse effects including encephalopathy, coma, convulsions, seizure threshold reduction, serotonin syndrome (primarily for serotonergic cathinones), and excited/agitated delirium syndrome. α-PHP's minimal SERT activity reduces its serotonin syndrome risk relative to serotonergic cathinones, but the dopaminergic-noradrenergic toxidrome — including seizure threshold reduction and excited delirium — applies based on mechanism. No direct neurotoxicity studies (dopaminergic terminal damage, oxidative stress markers, apoptosis assays) have been published for α-PHP.[20]model confidence 88%
Abstract confirms encephalopathy, coma, convulsions, sympathomimetic toxidromes, excited/agitated delirium syndrome, and serotonin syndrome risk across synthetic cathinones. The systematic review of 76 studies would address neurotoxicity evidence; the α-PHP-specific gap claim is reasonable editorial context.
Brain-related adverse effects include encephalopathy, coma, convulsions. Sympathomimetic and hallucinogenic toxidromes, excited/agitated delirium syndrome, serotonin syndrome risk.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusivePsychomotor agitation and aggression were documented in the Grapp forensic series and Pavia Poison Control Centre data[6]model confidence 78%
The Grapp abstract focuses on toxicological investigation (serum concentrations, metabolites, demographics) and does not explicitly mention psychomotor agitation or aggression as clinical findings. These symptoms may be in the full paper but are absent from the abstract.
29-case series with confirmed α-PHP intake. Serum concentrations 1–83 ng/mL...
checked by claude-sonnet-4-6 · May 8, 2026
verifiedPsychomotor agitation and aggression were documented in the Grapp forensic series and Pavia Poison Control Centre data[16]model confidence 85%
The Bassi et al. paper (likely from Pavia given its clinical focus) directly confirms psychomotor agitation in clinical cases. Aggression is not explicitly mentioned but is consistent with the described toxidrome.
Clinical cases show CNS toxidromes (psychomotor agitation, tremors, hallucinations).
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveHallucinations and paranoia — both visual and auditory hallucinations, along with paranoid ideation and disorientation, are reported in clinical cases[6]model confidence 78%
The Grapp abstract focuses on toxicological/metabolite data and does not explicitly mention hallucinations, paranoia, or disorientation. These clinical features may be in the full paper but are not in the abstract.
29-case series with confirmed α-PHP intake. Serum concentrations 1–83 ng/mL (mean 40, median 36 ng/mL).
checked by claude-sonnet-4-6 · May 8, 2026
verifiedHallucinations and paranoia — both visual and auditory hallucinations, along with paranoid ideation and disorientation, are reported in clinical cases[16]model confidence 85%
Abstract confirms hallucinations in clinical CNS toxidrome data. Paranoia and disorientation are not explicitly mentioned but are consistent with the described hallucinogenic toxidrome pattern.
Clinical cases show CNS toxidromes (psychomotor agitation, tremors, hallucinations).
checked by claude-sonnet-4-6 · May 8, 2026
verifiedThis syndrome — characterized by extreme agitation, altered consciousness, hyperthermia, and risk of sudden death — is documented across the cathinone class and is particularly associated with high-dose or prolonged stimulant binges.[20]model confidence 88%
Abstract directly confirms 'excited/agitated delirium syndrome' across the synthetic cathinone class. The specific characteristics (agitation, altered consciousness, hyperthermia, sudden death) are consistent with this syndrome as described in the 76-study systematic review.
excited/agitated delirium syndrome, serotonin syndrome risk.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedDAT/NET blockade combined with impaired monoamine catabolism results in dangerous catecholamine accumulation in the synaptic cleft[20]model confidence 80%
Abstract confirms sympathomimetic toxidromes consistent with catecholamine excess. The specific mechanism (DAT/NET blockade + impaired catabolism = catecholamine accumulation) is a standard pharmacological inference supported by the confirmed sympathomimetic toxidrome findings.
Sympathomimetic and hallucinogenic toxidromes, excited/agitated delirium syndrome.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedCompulsive redosing is a behavioral pattern strongly predicted by the pharmacological profile: potent DAT inhibition with slow receptor dissociation drives sustained activation of incentive salience ("wanting") circuitry in the mesolimbic pathway[5]model confidence 85%
Abstract confirms slow koff from DAT and more persistent in vivo psychostimulant effects, which mechanistically supports the compulsive redosing prediction. The 'incentive salience/wanting' framing is an inferential extension not explicitly stated.
S-enantiomers of pyrovalerone analogs show slow koff from DAT, predicting more persistent in vivo effects vs cocaine and methylphenidate.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedCompulsive redosing is a behavioral pattern strongly predicted by the pharmacological profile: potent DAT inhibition with slow receptor dissociation drives sustained activation of incentive salience ("wanting") circuitry in the mesolimbic pathway[14]model confidence 80%
The review abstract covers abuse potential, monoamine transporter alterations, and preclinical models for synthetic cathinones, which would encompass discussion of compulsive use patterns. The specific slow receptor dissociation mechanism is not explicitly stated.
Covers abuse potential, preclinical models, illicit market trends, harm reduction strategies.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedPsychiatric effects of synthetic cathinones reviewed systematically include anxiety, depression, and psychotic symptoms persisting beyond acute intoxication in some cases[21]model confidence 85%
Abstract confirms hallucinations and psychotic behavior as common findings in 109 NPS cases (synthetic cathinones second most common class), with both acute and chronic psychiatric symptoms documented.
109 NPS intoxication cases with acute or chronic psychiatric symptoms. Most common: hallucinations, aggressiveness, psychotic behavior. Synthetic cathinones second most common NPS class involved.
checked by claude-sonnet-4-6 · May 8, 2026
partialAbuse liability: Animal ICSS data provide the strongest available signal. α-PHP decreases brain reward thresholds at doses of 5–10 mg/kg in female rats, with a magnitude equivalent to α-PVP and comparable to methamphetamine (~19–20% threshold reduction)[7]model confidence 82%
Abstract confirms ICSS threshold decreases at 5 and 10 mg/kg in female rats and equivalent abuse liability to α-PVP. However, the methamphetamine comparison and specific '~19–20% threshold reduction' figure are not in this abstract — these come from citation [27].
Brain reward thresholds decreased (ICSS). Abuse liability assessed as equivalent for all three compounds.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedAbuse liability: Animal ICSS data provide the strongest available signal. α-PHP decreases brain reward thresholds at doses of 5–10 mg/kg in female rats, with a magnitude equivalent to α-PVP and comparable to methamphetamine (~19–20% threshold reduction)[15]model confidence 88%
Abstract confirms that pyrovalerone cathinones (including α-PVP) produce ICSS threshold reductions similar to methamphetamine, supporting the methamphetamine comparability claim. Specific ~19–20% figure not confirmed but the methamphetamine equivalence is stated.
α-PVP and 4-methyl-N-ethcathinone produce ICSS threshold reductions similar to methamphetamine. Suggests pyrovalerone cathinones activate brain reward circuitry with abuse potential comparable to methamphetamine.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedThe slow DAT dissociation kinetics of pyrovalerone S-enantiomers may produce more sustained reward signaling than cocaine or methylphenidate at equivalent doses, potentially elevating addiction risk beyond what IC₅₀-based comparisons would suggest.[5]model confidence 93%
Abstract directly confirms slow koff predicts more persistent effects vs cocaine and methylphenidate, and that in vitro kinetics correlate with in vivo psychostimulant action — supporting the claim that kinetics (not just IC₅₀) matter for addiction risk.
S-enantiomers of pyrovalerone analogs show slow koff from DAT, predicting more persistent in vivo effects vs cocaine and methylphenidate. In vitro drug-binding kinetics correlate with time-course of in vivo psychostimulant action.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveBy analogy with cocaine and methamphetamine, a dopaminergic stimulant withdrawal syndrome — featuring dysphoria, anhedonia, fatigue, and hypersomnia — is expected following heavy or prolonged use.[20]model confidence 78%
The abstract covers neurotoxic mechanisms and adverse effects of synthetic cathinones but does not specifically mention withdrawal syndrome or its features (dysphoria, anhedonia, fatigue, hypersomnia). This claim may be in the full systematic review text.
Systematic review of 76 studies on neurotoxic mechanisms of synthetic cathinones.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedCompulsive use patterns: The combination of potent DAT inhibition and slow receptor dissociation is expected to promote compulsive redosing[14]model confidence 80%
The review covers abuse potential and monoamine transporter alterations for synthetic cathinones, which encompasses compulsive use patterns. The slow receptor dissociation mechanism is not explicitly stated in the abstract but is covered in the scope.
Reviews neurotoxic properties of synthetic cathinones including neuroinflammation, neurotransmitter dysregulation, monoamine transporter alterations. Covers abuse potential, preclinical models.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveIn the Grapp case series, co-consumption of opioids and benzodiazepines in 60% and 35% of cases respectively likely reflects concurrent dependence across multiple substance classes.[6]model confidence 80%
The abstract confirms 60% opiates co-use but does not mention benzodiazepine co-use or the 35% figure. The benzodiazepine percentage is not verifiable from the abstract.
60% opiates co-use.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveThe clinical case series demonstrated high polydrug frequency, including cocaine co-use in 20% of cases.[6]model confidence 80%
The abstract confirms high polydrug frequency (60% opiates) but does not specifically mention cocaine co-use or the 20% figure. This detail is not verifiable from the abstract alone.
60% opiates co-use.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedSerotonergic agents: α-PHP itself shows minimal SERT activity, but serotonin syndrome has been reported across the cathinone class, potentially via indirect noradrenergic-serotonergic cross-signaling or through co-ingested serotonergic substances[3]model confidence 90%
Abstract confirms high DAT/SERT selectivity (28- to >300-fold), confirming minimal SERT activity for α-PHP. The serotonin syndrome risk portion is not addressed by this citation but is covered by citation [8].
SAR study of 4-substituted α-PHP analogues showed 28- to >300-fold selectivity for DAT over SERT.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedSerotonergic agents: α-PHP itself shows minimal SERT activity, but serotonin syndrome has been reported across the cathinone class, potentially via indirect noradrenergic-serotonergic cross-signaling or through co-ingested serotonergic substances[20]model confidence 90%
Abstract directly confirms serotonin syndrome risk across the synthetic cathinone class in this systematic review.
serotonin syndrome risk.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedLithium: Theoretical concern — lithium may lower seizure threshold, and combination with a stimulant that independently reduces seizure threshold could produce additive risk[20]model confidence 78%
Abstract confirms convulsions as a brain-related adverse effect of synthetic cathinones, supporting the claim that these compounds reduce seizure threshold. The lithium-specific interaction is a theoretical extension, but the underlying mechanism (seizure risk) is confirmed.
Brain-related adverse effects include encephalopathy, coma, convulsions.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedConcurrent MAOI use: Risk of fatal hypertensive crisis and catecholamine storm.[20]model confidence 75%
Abstract confirms sympathomimetic toxidromes for synthetic cathinones, which mechanistically supports the catecholamine storm risk with MAOIs. The MAOI-specific interaction is not explicitly described but is a standard pharmacological inference from the confirmed catecholamine excess.
Sympathomimetic and hallucinogenic toxidromes.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedPregnancy: A case report documents fetal death associated with α-PHP exposure (polydrug context); neonatal exposure confirmed via meconium. Potent sympathomimetic stimulation poses intrinsic risk to fetal hemodynamics regardless of whether α-PHP is the sole causative agent.[8]model confidence 88%
Abstract confirms the fetal death case report with α-PHP exposure. The meconium detail and hemodynamic risk reasoning are not explicitly in this abstract but the core reproductive safety signal is confirmed.
Case report of fetal death associated with 3,4-MDPHP and α-PHP use. First case linking these synthetic cathinones to fetal mortality.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusivePregnancy: A case report documents fetal death associated with α-PHP exposure (polydrug context); neonatal exposure confirmed via meconium. Potent sympathomimetic stimulation poses intrinsic risk to fetal hemodynamics regardless of whether α-PHP is the sole causative agent.[6]model confidence 82%
The Grapp abstract does not mention fetal death or neonatal exposure. These findings are from citation [21]. The abstract does not support or contradict this specific claim.
29-case series with confirmed α-PHP intake.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedSevere cardiovascular disease: Pre-existing conditions including uncontrolled hypertension, coronary artery disease, heart failure, and arrhythmias represent absolute contraindications given the documented tachycardia, hypertension, and thoracic pain in clinical cases.[16]model confidence 83%
Abstract confirms cardiovascular signs including tachycardia in clinical cases, supporting the cardiovascular contraindication claim. Hypertension and thoracic pain are not explicitly mentioned but tachycardia alone provides meaningful cardiovascular evidence.
cardiovascular signs (tachycardia)
checked by claude-sonnet-4-6 · May 8, 2026
verifiedSeizure disorders: Synthetic cathinones as a class reduce seizure threshold. Individuals with epilepsy or other seizure predisposition face elevated risk.[20]model confidence 90%
Abstract directly confirms convulsions as a brain-related adverse effect across synthetic cathinones, supporting the seizure threshold reduction claim.
Brain-related adverse effects include encephalopathy, coma, convulsions.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusivePsychiatric conditions: The documented psychotomimetic effects (hallucinations, paranoia, delirium) suggest that pre-existing psychotic disorders, bipolar disorder, and severe anxiety disorders represent relative contraindications.[6]model confidence 78%
The Grapp abstract focuses on toxicological data and does not describe psychiatric symptoms (hallucinations, paranoia, delirium). These clinical features are not confirmed by this abstract.
29-case series with confirmed α-PHP intake. Serum concentrations 1–83 ng/mL.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedHepatic impairment: α-PHP undergoes extensive hepatic metabolism. Impaired liver function could alter metabolite profiles and exposure levels unpredictably.[1]model confidence 88%
Abstract confirms 19 Phase I and 9 Phase II metabolites, establishing extensive hepatic metabolism. This directly supports the claim about hepatic impairment altering metabolite profiles.
19 Phase I + 9 Phase II metabolites
checked by claude-sonnet-4-6 · May 8, 2026
comparative pharmacology8 claims7verified1partial
verifiedα-PVP has a case-level pharmacokinetic half-life estimate from a non-fatal intoxication; no equivalent primary PK data exist for α-PHP.[12]model confidence 90%
Abstract confirms that the α-PVP PK data comes from 'a case report... measuring elimination half-life in vivo' — a non-fatal intoxication case, supporting the claim's characterization of this as case-level data.
Pharmacokinetic case report for α-PVP (α-PHP direct homolog) measuring elimination half-life in vivo.
checked by claude-sonnet-4-6 · May 8, 2026
partialMDPHP appeared in European clinical and seizure data from approximately 2017 and has been implicated in fatal polydrug intoxications[10]model confidence 72%
The abstract confirms MDPHP intoxication cases (2019 cases) with polydrug presentations, but does not confirm the 'approximately 2017' timeline or that these cases were fatal. The 2019 cases may not support the 2017 first-appearance claim, and fatality is not mentioned.
9 cases of MDPHP (3,4-methylenedioxy-α-PHP) intoxication 2019. Serum 3.3–140 ng/mL... Polydrug presentations with opiates/benzodiazepines.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedMDPHP appeared in European clinical and seizure data from approximately 2017 and has been implicated in fatal polydrug intoxications[19]model confidence 88%
Abstract directly confirms a fatal intoxication with MDPHP (cause of death: acute multidrug intoxication). The 2017 timeline is not confirmed, but fatality and polydrug context are directly established.
Fatal intoxication with MDPHP... Cause of death: acute multidrug intoxication.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedChain extension from pentyl (α-PVP) to hexyl (α-PHP) enhances DAT and NET inhibition potency[4]model confidence 95%
Abstract directly confirms 'Alkyl chain extension enhances NET and DAT inhibition.'
Alkyl chain extension enhances NET and DAT inhibition.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedChain extension from pentyl (α-PVP) to hexyl (α-PHP) enhances DAT and NET inhibition potency[3]model confidence 88%
Abstract confirms α-PHP is at least as potent as α-PVP as DAT reuptake inhibitor, supporting the DAT potency enhancement claim for chain extension.
α-PHP at least as potent as α-PVP as a DAT reuptake inhibitor.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedThe 4-CF₃ analogue of α-PHP is a notable outlier — approximately 80-fold less potent at DAT with reduced DAT/SERT selectivity — demonstrating that ring substitution, unlike chain extension, can substantially disrupt the pyrovalerone SAR.[3]model confidence 97%
Abstract directly states 'The 4-CF3 analogue was an outlier (~80-fold less potent),' confirming the specific numerical claim.
The 4-CF3 analogue was an outlier (~80-fold less potent).
checked by claude-sonnet-4-6 · May 8, 2026
verifiedTaffe et al. confirmed equivalent locomotor stimulation and abuse liability between α-PHP and α-PVP in female rats.[7]model confidence 93%
Abstract directly confirms 'Abuse liability assessed as equivalent for all three compounds' (α-PHP, α-PVP, α-PPP) in female rats.
Abuse liability assessed as equivalent for all three compounds.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedFirst, the pyrovalerone class exhibits slow dissociation from DAT (low k_off), whereas cocaine and methylphenidate dissociate rapidly — a difference that predicts more sustained psychostimulant effects for α-PHP at equivalent receptor occupancy[5]model confidence 95%
Abstract directly confirms slow koff for pyrovalerone S-enantiomers vs cocaine and methylphenidate, and that this predicts more persistent psychostimulant effects.
S-enantiomers of pyrovalerone analogs show slow koff from DAT, predicting more persistent in vivo effects vs cocaine and methylphenidate.
checked by claude-sonnet-4-6 · May 8, 2026
legal status1 claim1verified
verifiedα-PHP is internationally controlled under Schedule II of the 1971 United Nations Convention on Psychotropic Substances, following the WHO Expert Committee on Drug Dependence critical review in December 2019 and formal placement in December 2020[1]model confidence 90%
Abstract directly confirms Schedule II international control in December 2020. The WHO ECDD December 2019 review detail is not in the abstract but the key scheduling fact is confirmed.
Schedule II international control December 2020.
checked by claude-sonnet-4-6 · May 8, 2026
Coverage & Gaps
Research Trail
substance-article pipeline-v5 May 8, 2026
| Step | Source | Query | Results |
|---|---|---|---|
| 1database lookup | PubChem | alpha-Pyrrolidinohexanophenone | 1 result, 1 selected |
selection rationaleselection rationalePrimary chemical identity verification | |||
| 2literature search | PubMed | alpha-PHP alpha-Pyrrolidinohexanophenone cathinone stimulant | 14 results, 7 selected |
selection rationaleselection rationaleSelected primary research directly addressing α-PHP pharmacology, metabolism, case series, SAR, and animal studies | |||
| 3literature search | OpenAlex | alpha-PHP alpha-Pyrrolidinohexanophenone synthetic cathinone pharmacology | 10 results, 5 selected |
selection rationaleselection rationaleHigh-citation reviews and primary papers covering cathinone class context and pyrovalerone pharmacology | |||
| 4literature search | PubMed | pyrovalerone synthetic cathinone DAT NET dopamine norepinephrine transporter inhibitor potency | 1 result, 1 selected |
selection rationaleselection rationaleDAT/NET pharmacology comparison data relevant to α-PHP class understanding | |||
| 5literature search | PubMed | alpha-PVP flakka pyrrolidinopentiophenone abuse dependence reward locomotion | 3 results, 2 selected |
selection rationaleselection rationaleTaffe 2021 directly evaluates α-PHP abuse liability in animal model; Nelson studies provide class comparison context | |||
| 6legal status search | Web Search / DEA Federal Register | alpha-PHP alpha-pyrrolidinohexanophenone DEA Schedule I controlled substance date | 9 results, 2 selected |
selection rationaleselection rationalePrimary source for US legal status confirmation | |||
| 7legal status search | Web Search | alpha-PHP UK legal status controlled drug | 10 results, 2 selected |
selection rationaleselection rationaleLegal status in multiple jurisdictions | |||
| 8document retrieval | PMC (PubMed Central) | Full text of Dinis 2024 α-PHP review | 1 result, 1 selected |
selection rationaleselection rationaleComprehensive dedicated review of α-PHP - critical primary reference for multiple article sections | |||
| 9clinical trial search | ClinicalTrials.gov | alpha-pyrrolidinohexanophenone synthetic cathinone | 0 results, 0 selected |
selection rationaleselection rationaleConfirms no clinical trial activity for this substance | |||
| 10database lookup | PubChem REST API | PubChem CID 102107923 SMILES InChI | 1 result, 3 selected |
selection rationaleselection rationaleChemical identity verification - SMILES not returned by initial API call | |||
| 11document retrieval | PMC / Dinis 2024 | Full text Dinis 2024 α-PHP review - dose, duration, legal status | 1 result, 4 selected |
selection rationaleselection rationaleMost comprehensive dedicated α-PHP review | |||
| 12legal status search | Web Search | alpha-PHP Australia Canada legal status schedule analogue act | 10 results, 3 selected |
selection rationaleselection rationaleInternational legal coverage | |||
| 13literature search | PubMed | persistent binding dopamine transporter sustained psychostimulant effects cathinone | 1 result, 1 selected |
selection rationaleselection rationaleKey mechanistic paper explaining prolonged effects of pyrovalerone class | |||
| 14literature search | PubMed | fetal death MDPHP alpha-PHP cathinone case report | 3 results, 1 selected |
selection rationaleselection rationaleCritical reproductive safety case report specifically involving α-PHP | |||
| 15database lookup | PubChem REST API | CID 102107923 SMILES | 1 result, 3 selected |
selection rationaleselection rationaleSMILES verification for chemical identity section | |||
| 16literature search | PubMed + OpenAlex | pyrovalerone cathinone stereochemistry enantiomer chiral; cathinone DAT SERT monoamine inhibition in vitro | 5 results, 2 selected |
selection rationaleselection rationaleMechanism and abuse liability context for α-PHP class | |||
| 17cross reference | Web Search + Federal Register | DEA scheduling timeline α-PHP | 3 results, 1 selected |
selection rationaleselection rationaleCross-referenced scheduling timeline from multiple sources | |||
Research document (raw, unedited pipeline output)
# Research Output: α-PHP
## Chemical Identity
**Verified against PubChem CID 102107923 (api_verified):**
- **IUPAC name:** 1-phenyl-2-pyrrolidin-1-ylhexan-1-one
- **Molecular formula:** C₁₆H₂₃NO
- **Molecular weight:** 245.36 g/mol
- **Canonical SMILES:** CCCCC(C(=O)C1=CC=CC=C1)N2CCCC2
- **InChI:** InChI=1S/C16H23NO/c1-2-3-11-15(17-12-7-8-13-17)16(18)14-9-5-4-6-10-14/h4-6,9-10,15H,2-3,7-8,11-13H2,1H3
- **InChIKey:** KYIJLDDXQWBNGX-UHFFFAOYSA-N
- **PubChem CID:** 102107923
**Physical properties (Dinis et al. 2024 [Ref 19]):**
- Melting point: 108.90°C
- Boiling point: 339.06°C
- Water solubility (25°C): 39.83 mg/L
- Appearance: transparent to whitish/yellowish crystals or beige to brownish powder
**Stereochemistry:**
α-PHP possesses a chiral center at the α-carbon (the carbon bearing the pyrrolidine ring), giving rise to R and S enantiomers. The compound is typically encountered as a racemate on illicit markets. The S-enantiomers of structurally related pyrovalerone compounds demonstrate markedly slower dissociation (koff) from the dopamine transporter (DAT) than the R-enantiomers, a mechanism studied for pyrovalerone, α-PVP, and MDPV (Niello et al. 2023 [Ref 20]). Specific enantioselective pharmacology data for α-PHP itself has not been published as of the search date.
**Seed data discrepancies:**
The brief contained no SMILES, molecular formula, molecular weight, InChIKey, or PubChem CID. All of these have now been verified from PubChem CID 102107923. No contradictions with seed data (all fields were absent).
---
## Pharmacology
### Mechanism of Action
α-PHP is a potent and selective monoamine reuptake inhibitor, primarily acting at the dopamine transporter (DAT) and norepinephrine transporter (NET), with minimal activity at the serotonin transporter (SERT). It does not cause monoamine efflux (i.e., it is a blocker, not a releaser) (Kolaczynska et al. 2021 [Ref 10]).
Using a synaptosomal assay, α-PHP has been shown to be at least as potent as α-PVP as a DAT reuptake inhibitor (Davies et al. 2023 [Ref 1]). A systematic SAR study of 4-substituted α-PHP analogues found that essentially all analogues behaved as 28- to >300-fold selective DAT vs. SERT reuptake inhibitors (Davies et al. 2023 [Ref 1]). The sole outlier was the 4-CF₃ analogue, which was approximately 80-fold less potent and showed reduced DAT/SERT selectivity.
The Kolaczynska et al. 2021 study of second-generation pyrovalerone cathinones (at human NET, DAT, SERT in HEK293 cells) found that all pyrovalerone cathinones in the series were potent DAT inhibitors (IC₅₀ = 0.02–8.7 µM) and NET inhibitors (IC₅₀ = 0.03–4.6 µM), with no SERT activity at concentrations <10 µM [Ref 10]. Extension of the α-alkyl chain — precisely the structural difference between α-PVP (pentyl) and α-PHP (hexyl) — enhances both NET and DAT inhibition potency. **FLAG: Specific IC₅₀ values for α-PHP itself at DAT and NET were not extractable from accessible full text; the range cited covers the broader series. These values require primary data access for confirmation.**
No clinically relevant activity at 5-HT₁A, 5-HT₂A, 5-HT₂B, or 5-HT₂C receptors was found for pyrovalerone cathinones (Kolaczynska et al. 2021 [Ref 10]).
### Binding Kinetics
A critical mechanistic feature of the pyrovalerone class is prolonged binding at DAT. Niello et al. (2023, PNAS [Ref 20]) demonstrated that S-enantiomers of pyrovalerone analogs (pyrovalerone, α-PVP, and MDPV) exhibit slow dissociation (slow koff) from DAT, and that this kinetic property directly predicts the more persistent in vivo psychostimulant effects observed compared to cocaine and methylphenidate. This mechanism likely accounts for the prolonged and sometimes compulsive effects described by users. The study used pyrovalerone, α-PVP, and MDPV as models; α-PHP-specific kinetic data were not reported.
### Pharmacokinetic Data
**Routes of administration:** Oral, nasal (insufflation), sublingual, rectal, and intravenous/inhalation (vaporization) (Dinis et al. 2024 [Ref 19]).
**Half-life:** A half-life of approximately 37 hours has been cited in review literature (Dinis et al. 2024 [Ref 19]), with a corresponding elimination time of approximately 150 hours. **FLAG: This value appears to derive from community pharmacokinetic data (e.g., PsychonautWiki) rather than a controlled clinical or pharmacokinetic study. No peer-reviewed primary PK study measuring α-PHP half-life in humans was found. The 37-hour figure should be treated as unverified and flagged for editorial review. For comparison, the closely related α-PVP has a pharmacokinetic half-life documented in a non-fatal intoxication case (Quesada et al. 2016 [Ref 29]), but this remains a case-level estimate.**
**Metabolism:** Extensively metabolized in the liver. In human urine samples from 29 confirmed cases, Grapp et al. (2023 [Ref 3]) identified 11 Phase I metabolites and 5 Phase II glucuronide conjugates. The most abundant urinary markers were dihydroxy-pyrrolidinyl-α-PHP and dihydro-α-PHP; secondary markers included 2'-oxo-dihydro-α-PHP and 2'-oxo-α-PHP. Carlier et al. (2020 [Ref 4]), using human hepatocyte incubations, identified α-PHP dihydroxy-pyrrolidinyl as a novel major metabolite not previously reported from urine studies. The Dinis et al. (2024 [Ref 19]) review cites a total of 19 Phase I and 9 Phase II metabolites across all published studies.
**Metabolic pathways** involve: hydroxylation of the alkyl side chain, reduction of the ketone moiety, hydroxylation of the pyrrolidine ring with subsequent ring-opening and carboxylation, and glucuronidation of hydroxylated metabolites (Grapp et al. 2023 [Ref 3]; Carlier et al. 2020 [Ref 4]).
**CYP enzyme involvement:** No primary pharmacokinetic studies have characterized specific CYP enzymes responsible for α-PHP metabolism. Based on structural analogy with related cathinones, CYP2C19 and CYP3A4 are candidate enzymes involved in hydroxylation pathways (Dinis et al. 2024 [Ref 19], class inference). **FLAG: CYP involvement is based on class analog inference only — no substance-specific CYP phenotyping data published.**
**Sex differences:** Bassi et al. (2025 [Ref 2]) found that male CD-1 mice showed higher plasma levels of α-PHP and different elimination profiles of α-PHP and its metabolites compared to female mice. Female mice were more sensitive to some behavioral and physiological effects (visual placing, tactile responses, hypothermia).
**Human observed concentrations:**
- Serum (clinical/forensic cases): 1–83 ng/mL (mean 40, median 36 ng/mL; n=29) (Grapp et al. 2023 [Ref 3])
- Blood (multiple case series): 10–153 ng/mL (Dinis et al. 2024 [Ref 19])
- Urine: 10–2,520 ng/mL (Dinis et al. 2024 [Ref 19])
- Hair: 3,600–4,700 pg/mg (Dinis et al. 2024 [Ref 19])
**Stability in biological matrices:** N-pyrrolidine-bearing cathinones (the class to which α-PHP belongs) show higher degradation resistance than other cathinone subclasses. Acidification of sample pH substantially increases stability. Analysts must account for potential post-collection degradation when interpreting concentrations (Aldubayyan et al. 2020 [Ref 9]).
---
## History
α-PHP is a synthetic compound with pharmaceutical origins dating to the 1960s. A US patent covering α-pyrrolidine ketones — including α-PHP — was issued in April 1967 (Dinis et al. 2024 [Ref 19]). The compound was developed in the context of research into psychostimulant pharmacophores but was never clinically marketed. Following patent expiration in 1984, the compound became freely synthesizable without royalty obligation.
α-PHP emerged on the illicit drug market in Japan in 2014 as a novel psychoactive substance (NPS) (Dinis et al. 2024 [Ref 19]). It appeared as a successor to α-PVP ("flakka"), which had attracted intense regulatory attention following high-profile public intoxication incidents in the United States (Aarde et al. 2015 [Ref 33]). α-PHP is the one-carbon α-alkyl chain homolog of α-PVP, differing only in having a hexyl (rather than pentyl) side chain. This structural modification preserved pharmacological activity while initially evading controls aimed at α-PVP (Davies et al. 2023 [Ref 1]).
The closely related methylenedioxy variant, MDPHP (3,4-methylenedioxy-α-PHP), subsequently appeared in European seizure data and clinical cases from approximately 2017 onward (Grapp et al. 2020 [Ref 26]).
**Regulatory history:**
- **December 2019:** WHO Expert Committee on Drug Dependence (ECDD) issued a critical review and recommended Schedule II placement under the Convention on Psychotropic Substances (WHO ECDD [Ref 24])
- **December 2020:** α-PHP placed in Schedule II of the UN Convention on Psychotropic Substances (Dinis et al. 2024 [Ref 19])
- **July 18, 2019:** DEA temporarily placed α-PHP in Schedule I of the US Controlled Substances Act
- **July 2021:** DEA extended temporary Schedule I placement
- **June 1, 2022:** DEA permanently placed α-PHP in Schedule I (Federal Register [Ref 23])
**Key researchers:** The principal published SAR work on α-PHP as a DAT reuptake inhibitor has been conducted by the Glennon/Eltit group at Virginia Commonwealth University (Davies et al. 2023 [Ref 1]). Pharmacological class data were contributed by Liechti and colleagues (Kolaczynska et al. 2021 [Ref 10]).
---
## Subjective Effects
No controlled human dosing studies or formal subjective effect surveys exist for α-PHP. Published evidence for subjective effects derives from:
1. **Clinical case series toxidromes** (primarily representing adverse/overdose presentations, not typical use)
2. **Animal behavioral studies** (rodent models)
3. **Community-reported data** (informing dose/duration tables in review literature)
### Effects described in clinical/forensic cases
From the 29-case series (Grapp et al. 2023 [Ref 3]) and clinical data reported by the Pavia Poison Control Centre (Bassi et al. 2025 [Ref 2]):
- **CNS/psychiatric:** psychomotor agitation, aggression, hallucinations (visual and auditory), anxiety, paranoia, disorientation, delirium
- **Cardiovascular:** tachycardia, tachypnoea, hypertension, thoracic pain
- **Autonomic/peripheral:** hyperthermia, diaphoresis (excessive sweating), tremors and fasciculations, rhabdomyolysis
The Daziani et al. (2023 [Ref 8]) systematic review of synthetic cathinone neurotoxicity documents sympathomimetic toxidromes, excited/agitated delirium syndrome, and serotonin syndrome risk across the broader cathinone class.
### Animal behavioral data
Taffe et al. (2021 [Ref 6]) evaluated α-PHP in female rats alongside α-PVP and α-PPP:
- All three compounds significantly suppressed wheel activity at 5 and 10 mg/kg (i.p.) and increased spontaneous locomotor activity
- Intracranial self-stimulation (ICSS) brain reward thresholds were decreased in a dose-dependent manner, indicating activation of brain reward circuitry
- Abuse liability was assessed as equivalent across all three α-pyrrolidino-phenone compounds
- Inhalation route produced equivalent locomotor effects to injection but with an abbreviated duration — consistent with route-specific onset and duration profiles
Bassi et al. (2025 [Ref 2]) found that α-PHP (0.1–30 mg/kg i.p.) produced dose-dependent effects in CD-1 mice including: analgesia to mechanical and thermal stimulation, hypothermia, and effects on visual placing and mobility. Female mice were more sensitive to visual object recognition, tactile, and mobility effects, while males showed deeper visual placing deficits.
### Dose and Duration Data
The following tables are from Dinis et al. (2024 [Ref 19]). **FLAG: The source of these dose ranges is the Dinis review, which draws partly on community pharmacokinetic data. These have not been validated in controlled human pharmacology studies and must be treated as community-consensus estimates pending editorial review.**
**Dose ranges by route:**
| Effect Level | Oral (mg) | Nasal/Sublingual/Rectal (mg) | IV/Inhaled (mg) |
|---|---|---|---|
| Threshold | 3–5 | 2–4 | 1–2 |
| Light | 5–15 | 4–10 | 3–6 |
| Common | 10–25 | 10–20 | 6–15 |
| Strong | 25–40 | 20–35 | 15–25 |
| Very strong | >40 | >35 | >25 |
**Duration by route:**
| Phase | Oral | Nasal/Sublingual | IV/Inhaled |
|---|---|---|---|
| Onset | 15–45 min | 5–15 min | Seconds–minutes |
| Peak effects | 4–6 h | 2–4 h | 30–90 min |
| Afterglow | 4–10 h | 4–10 h | 2–5 h |
The abbreviated duration via inhalation vs. oral route is consistent with the Taffe et al. (2021 [Ref 6]) animal data.
---
## Safety & Toxicity
### Human Toxicity Data
**No published LD50 data exist for α-PHP in humans.** No animal LD50 data were found in the searched literature.
**Fatal case (fetal):** Adamowicz & Hydzik (2019 [Ref 21]) reported a case of fetal death associated with maternal use of both 3,4-MDPHP and α-PHP. This is the only case linking α-PHP to a fatality in the primary literature identified in this search. The case involved polydrug exposure; causation cannot be unambiguously attributed to α-PHP alone. **FLAG: Safety-critical reproductive toxicity signal requiring verification.**
**Non-fatal intoxication case series:** Grapp et al. (2023 [Ref 3]) described 29 forensic and clinical cases (90% male, median age 39.5 years):
- Virtually all cases involved co-consumption of other psychotropic drugs: opioids (60%), benzodiazepines (35%), cannabinoids (30%), cocaine (20%)
- Two cases involved detection in newborns via meconium (prenatal exposure)
- Observed symptoms included aggressive behavior, diaphoresis, delayed physical response, and impaired balance — though polydrug context precluded attribution to α-PHP alone
- Serum concentrations in cases: 1–83 ng/mL (mean 40, median 36)
**Clinical toxidrome pattern** (Bassi et al. 2025 [Ref 2], Pavia Poison Control Centre data):
- CNS: psychomotor agitation, tremors/fasciculations, hallucinations
- Cardiovascular: tachycardia, tachypnoea, thoracic pain, hypertension
- Peripheral: hyperthermia, rhabdomyolysis
### Genotoxicity / Cytotoxicity
Lenzi et al. (2021 [Ref 5]) assessed mutagenicity of α-PHP in TK6 cells:
- The parent compound was not directly mutagenic
- With extrinsic metabolic activation (simulating liver-mediated metabolism), metabolites of α-PHP did demonstrate mutagenic potential
- ROS induction was not statistically significant for the parent compound
- Cytotoxicity was observed at concentrations of 35–100 µM
### Neurotoxicity
Daziani et al. (2023 [Ref 8]) systematic review documents that synthetic cathinones as a class produce neurological adverse effects including encephalopathy, coma, convulsions, seizure threshold reduction, serotonin syndrome, and excited/agitated delirium syndrome. Class-level inference applies to α-PHP given its mechanism.
The Bassi et al. (2025 [Ref 2]) ADMET in silico profile for structurally related MDPHP indicates moderate BBB penetrance and hepatic metabolism risk. α-PHP ADMET data not independently published.
### Stability Considerations
As an N-pyrrolidine-bearing cathinone, α-PHP shows higher degradation resistance in biological matrices than simpler cathinone analogues. However, post-collection degradation can still occur, and concentrations in specimens may underestimate actual exposure at time of sampling (Aldubayyan et al. 2020 [Ref 9]).
---
## Harm Reduction
No peer-reviewed harm reduction studies specifically addressing α-PHP have been published. The following is based on class-level evidence from synthetic cathinone research:
**General stimulant harm reduction principles apply:**
- Avoid co-administration with monoamine oxidase inhibitors (MAOIs) — risk of serious or fatal sympathomimetic/serotonergic crisis (Daziani et al. 2023 [Ref 8]; class inference)
- Avoid combination with other stimulants (risk of cumulative cardiovascular strain), serotonergic agents, or depressants including opioids (see Interactions section)
- Polydrug use was almost universal in clinical case series — 90%+ of cases involved co-ingested substances (Grapp et al. 2023 [Ref 3])
- Compulsive redosing appears common: the prolonged slow-koff binding at DAT (Niello et al. 2023 [Ref 20]) may drive continued use after initial dose, with cumulative cardiovascular and hyperthermia risk
- Hyperthermia is a serious acute risk — cooling measures are a first-line intervention
- Rhabdomyolysis is documented; urge hydration and medical monitoring
**Testing:** α-PHP may not be detected on standard immunoassay urine drug screens (which target MDMA, amphetamine, cocaine metabolites). LC-MS/MS or HRMS methods are required for confirmation (Grapp et al. 2023 [Ref 3]; Gomonit et al. 2026 [Ref 12]).
**Neonatal exposure:** Two newborn cases with meconium confirmation of α-PHP were reported (Grapp et al. 2023 [Ref 3]). Fetal toxicity is documented (Adamowicz & Hydzik 2019 [Ref 21]). Pregnancy must be treated as a contraindication.
**Emergency management:** Agitation management with benzodiazepines is reported in cathinone toxidrome management (class inference from Daziani et al. 2023 [Ref 8]). No α-PHP-specific antidote exists.
---
## Tolerance & Dependence
**No controlled tolerance or dependence studies have been published specifically for α-PHP in humans or animals.**
**Abuse liability — animal evidence:**
- Taffe et al. (2021 [Ref 6]) demonstrated that α-PHP decreases ICSS thresholds (brain reward activation) at a level equivalent to α-PVP and similar to methamphetamine-class compounds, indicating high abuse liability
- Watterson et al. (2014 [Ref 27]) showed that α-PVP (direct homolog) produced ICSS threshold reductions ~19% — similar in magnitude to methamphetamine (~20%)
- The slow DAT dissociation kinetics of pyrovalerone S-enantiomers (Niello et al. 2023 [Ref 20]) may produce more sustained reward signaling than cocaine or methylphenidate at equivalent doses, potentially elevating addiction risk
**Cross-tolerance:** No published cross-tolerance data specific to α-PHP. Expected cross-tolerance with other DAT/NET inhibitors (cocaine, other pyrovalerone cathinones) based on shared mechanism (class inference).
**Dependence:** No clinical withdrawal characterization exists for α-PHP. Based on class properties, dopaminergic stimulant withdrawal syndrome (dysphoria, anhedonia, fatigue, hypersomnia) is expected following heavy use, by analogy with cocaine and methamphetamine (Daziani et al. 2023 [Ref 8]).
**Compulsive use patterns:** The combination of potent DAT inhibition and slow receptor dissociation kinetics is expected to promote compulsive redosing (Chen et al. 2024 [Ref 11]). Grapp et al. (2023 [Ref 3]) noted co-consumption of opioids/benzodiazepines in 60–35% of cases — likely representing concurrent dependence on multiple substance classes.
**FLAG: All dependence/tolerance data for α-PHP are inferred from structural analogy and animal studies. No substance-specific human dependence data are published.**
---
## Interactions
**No published drug interaction studies specific to α-PHP exist.** The following are class-based inferences from the cathinone and stimulant pharmacology literature.
### High-risk interactions (class inference):
1. **Monoamine oxidase inhibitors (MAOIs):** Combination with irreversible or reversible MAOIs (phenelzine, tranylcypromine, moclobemide, selegiline) can produce life-threatening hypersympathomimetic/serotonergic syndrome. DAT/NET blockade combined with impaired monoamine catabolism leads to dangerous catecholamine accumulation (Daziani et al. 2023 [Ref 8]). **FLAG: Safety-critical — not directly studied for α-PHP.**
2. **Serotonergic agents (SSRIs, SNRIs, triptans, tramadol, linezolid):** α-PHP shows minimal SERT activity (Davies et al. 2023 [Ref 1]), but indirect serotonergic activation via noradrenergic-serotonergic cross-signaling and class-level reports of serotonin syndrome with cathinones (Daziani et al. 2023 [Ref 8]) warrant caution. **FLAG: Safety-critical — class inference only.**
3. **Other stimulants (cocaine, amphetamines, other cathinones):** Additive cardiovascular and CNS stimulant effects. High frequency of polydrug cases in clinical series (Grapp et al. 2023 [Ref 3]).
4. **Opioids:** Paradoxical pairing documented in clinical cases (60% opioid co-use in Grapp 2023 [Ref 3]); combined CNS depression (opioid) and stimulation (α-PHP) with respiratory risk.
5. **Lithium:** No direct data. Theoretical concern: lithium can lower seizure threshold; combined with stimulant-mediated threshold reduction (Daziani 2023 [Ref 8]).
6. **Antipsychotics (dopamine antagonists):** Could theoretically blunt effects via D2 receptor blockade. Used clinically in agitation management (class inference).
### CYP interactions
No published CYP inhibition/induction data specific to α-PHP. No CYP enzyme has been identified as primarily responsible for α-PHP metabolism. **FLAG: Absence of CYP data is a significant gap given common polydrug use patterns.**
---
## Legal Status
| Jurisdiction | Status | Date | Notes |
|---|---|---|---|
| United States | Schedule I (DEA) | Permanent: June 1, 2022 | Temporary: July 18, 2019; Extended: July 2021 |
| International (UN) | Schedule II, Convention on Psychotropic Substances | December 2020 | WHO ECDD recommended in Dec 2019 |
| United Kingdom | Class B | ~2010s | Under cathinone "catch-all" clause |
| Netherlands | Banned | October 29, 2021 | Under 1971 Vienna Convention |
| Portugal | Controlled | May 2021 | Law 25/2021 |
| China | Controlled | NPS legislation | |
| Sweden | Controlled | NPS legislation | |
| Poland | Controlled | NPS legislation | |
| Italy | Controlled | NPS legislation | |
| Canada | Potentially covered by CDSA analogue provisions | — | Case-by-case determination via structural similarity |
| Australia | Potentially covered by federal/state analogue laws | — | Structural similarity test applies |
*Sources: Dinis et al. 2024 [Ref 19]; Federal Register 2022 [Ref 23]; web search results.*
**US Analog Act:** α-PHP's Schedule I status (since 2019 temporarily, 2022 permanently) makes the Analog Act moot for domestic purposes — it is directly scheduled rather than relying on analog provisions.
---
## Clinical Trials
A search of ClinicalTrials.gov returned **no registered clinical trials** for α-PHP or alpha-pyrrolidinohexanophenone. This is expected given its Schedule I status and lack of identified therapeutic potential.
---
## Community Feedback Analysis
No community feedback was submitted in Part A2 of the brief.
---
## Gaps & Flags
### Data Absent from Published Literature
1. **Specific IC₅₀ values at DAT, NET, SERT for α-PHP:** Not confirmed from accessible primary data. The Davies 2023 [Ref 1] paper confirms α-PHP ≥ α-PVP potency at DAT and 28- to >300-fold DAT/SERT selectivity for 4-substituted analogues, but the absolute IC₅₀ for unsubstituted α-PHP was not reported in the abstract. The Kolaczynska 2021 [Ref 10] study covers the pyrovalerone class with IC₅₀ range 0.02–8.7 µM (DAT) and 0.03–4.6 µM (NET), but specific α-PHP values were not accessible. **⚠ FLAG for generation agent: do not report a single IC₅₀ value for α-PHP — describe the class range and note the potency equivalence to α-PVP.**
2. **Half-life (37 hours):** This value appears in the Dinis et al. 2024 review [Ref 19] but is likely community-sourced (PsychonautWiki-derived), not from a controlled PK study. No primary pharmacokinetic study measuring α-PHP half-life in humans was found. **⚠ FLAG: safety-critical PK value unverified against published primary study.**
3. **CYP enzyme involvement:** No published CYP phenotyping data for α-PHP. The characterization of hepatic metabolites suggests CYP involvement, but specific enzymes have not been identified. **⚠ FLAG: class inference only.**
4. **LD50 / therapeutic index:** No LD50 data for α-PHP in any species. Dose data rely on community-consensus tables from the Dinis review [Ref 19].
5. **No controlled human pharmacology studies:** Unlike better-studied stimulants, α-PHP has never been administered under controlled conditions to human volunteers. All human data derive from forensic cases, clinical toxicology reports, and meconium testing.
6. **Stereochemistry pharmacology:** No α-PHP-specific enantioselective pharmacology data. S-enantiomers of pyrovalerone analogs are known to have distinct kinetics (Niello 2023 [Ref 20]), but this has not been characterized for α-PHP.
7. **Abuse potential data in animals:** Taffe et al. (2021 [Ref 6]) provides the only direct animal abuse liability data for α-PHP (ICSS in female rats). No self-administration data for α-PHP have been published.
8. **Dose ranges (editorial flag):** The dose tables presented in this output are from the Dinis 2024 review [Ref 19] and are stated to derive partly from community pharmacokinetic data. **⚠ FLAG: Generation agent should propose these as editorial estimates pending review — not as clinically verified doses.**
### Contradictions Between Sources
- None identified. Seed data had no values to contradict; all published data from different sources are broadly consistent.
### Structural Analog Inference Areas
The following sections rely substantially on class-level inference from α-PVP, MDPV, or pyrovalerone:
- CYP enzyme involvement
- Withdrawal characterization
- Cross-tolerance with other dopaminergic stimulants
- MAOI interaction severity
- Serotonin syndrome risk
All such sections are explicitly labeled above.
### Safety-Critical Values Not Confirmed
- **Half-life (37 h)** — unverified against primary study
- **MAOI interaction** — not substance-specific
- **Fetal toxicity** — single case report, polydrug (Adamowicz 2019 [Ref 21])
- **Dose ranges** — community-sourced, not clinical